

REMARKS

Applicants request entry of the amendments and reconsideration of the application.

Amendment to the Specification

The amendment to the specification corrects typographical or inadvertent errors and does not add new matter. As noted in the Appendix A, which shows the changes made, the errors relate to the abbreviated titles of journal references and the form and completeness of the citations to these journal references.

Claims 17-36 have been canceled and new claims 37-76 have been added.

The amendments to the claims reflect the selection of SEQ ID NO: 17 and 18 for examination, as required by the Examiner in his objections to the claims (see page 4 of Paper No. 19). Applicants specifically reserve the right to seek patents for all the sequences and subject matter disclosed in the application and original claims. The changes in the recitation of the polynucleotides of the claims are made to better reflect the disclosures in the specification and in the priority document. The amendments are not made for reasons of patentability.

As shown below, no new matter enters by the new claims and the specification enables the new claims.

The new claims are directed to transcription factors that have at least 42% amino acid sequence identity with the AP2 transcription factor of SEQ ID NO: 18, and have enhanced plant disease tolerance due to changed expression or activity of the transcription factor. These claims are disclosed and enabled by the text of the specification at, for example, page 17, lines 6-9; page 13, lines 13-23; page 22, lines 34-35; page 23, lines 36-37 and continued on page 24, lines 1-4; page 25, lines 6-11; at page 11, lines 21-22, which discloses "[t]ranscription factors that are homologs of the disclosed sequences will typically share at least 40% amino acid sequence identity"; and at page 25, lines 4-9, which discloses that G19 (SEQ ID NO:22) expression was significantly induced upon infection by the fungal pathogen *Erysiphe* and G19-overexpressing plants were more tolerant to *Erysiphe* infection; and by Figure 1, which discloses the AP2-family transcription factors G1006 (SEQ ID NO: 34), G19 (SEQ ID NO:22), G4 (SEQ ID NO:12) and

G25 (SEQ ID NO: 34), which, as shown below, share 60%, 42%, 42%, and 54% amino acid sequence identity with G28 (SEQ ID NO:18), respectively.

As shown in the attached Appendix B providing experimental expression data, G1006 and G25 expression is induced in response to exposure to different disease agents. As shown in the executed declaration of Dr. Jacqueline Heard (the Heard Declaration, attached as Appendix C), G1006, G19, G4 and G25 expression has been shown to be up-regulated by *Fusarium*, *Erysiphe*, *Botrytis* exposure or infection, and methyl jasmonate in microarray analyses (see in particular the Heard Declaration, Exhibits A through G of the Declaration). As disclosed in the specification and stated in the Heard Declaration, the jasmonic acid signal transduction pathway is involved in the regulation of the defense response; the regulation of G4 expression by both hormones, its induction upon *Erysiphe orontii* infection, as well as the preliminary data indicating that increased tolerance to that pathogen is conferred by G19 overexpression, suggest that these transcription factors control the defense response. Thus, evidence is provided that shows AP2 family transcription factors with at least 42% identity to SEQ ID NO:18 (G28) either induce enhanced tolerance to plant disease or provide enhanced tolerance based on sequence similarity and expression profiles, thus likely endowing a plant with increased pathogen resistance (as would be recognized by one skilled in the art; see the Heard declaration, sections 8 to 9).

As also shown in Heard Declaration, the function of SEQ ID NOs:17 and 18 (G28) was more recently analyzed using transgenic plants in which this gene was expressed under the control of the 35S promoter. G28 overexpressing lines were shown to be more tolerant to infections by *Erysiphe orontii*, *Sclerotinia sclerotiorum* or *Botrytis cinerea*. Thus, the disclosure in the specification, that the transcription factors recited in the claims, including G28, could be used to produce plants that are more tolerant to disease, has been confirmed by experimentation. (See, for example, page 7, lines 22-28, page 17, lines 10-17, page 19, line 31 through page 21, line 28, page 24, line 9 through page 25, line 13.)

The new claims are also directed to transcription factors that comprise a conserved domain of a plant AP2 transcription factor wherein the conserved domain comprises one of an amino acid sequence of residues 145-213 of the AP2 transcription factor of SEQ ID NO: 18, or

an amino acid sequence having at least 84% identity to residues 145-213 of the AP2 transcription factor of SEQ ID NO: 18, or an amino acid sequence of residues 145-213 of the AP2 transcription factor of SEQ ID NO: 18 having one or more conservative substitutions, deletions, or insertions. Applicants clearly identified amino acid residues 145-213 of the AP2 transcription factor of SEQ ID NO: 18 in Figure 1a (see SEQ ID NO: 18, G28, in particular). Also, the specification at page 10, lines 13-14, specifically notes the conservative substitutions, deletions, and insertions of which one of skill in the art would be aware. Further support for residues that may be substituted and with which residues they may be substituted is disclosed in Table 1 at page 46 of provisional Application serial No. 60/125,814, from which the instant application claims priority. In addition, fragments of domains of transcription factor sequences are specifically disclosed at page 4, lines 32-37, and in Figure 1.

Applicants also note that SEQ ID NO: 22 (G19) is disclosed in the specification as being significantly induced upon infection by the fungal pathogen *Erysiphe orontii* (see specification at page 25, lines 4-9). As shown in the accompanying BLAST report (Appendix F), the conserved domains of G28 (SEQ ID NO: 18) show substantial sequence identity to G19 (SEQ ID NO: 22), namely 60% identity (see Appendix F: BLAST report, page number listed as 12 or 28; handwritten notes regarding % identity provided by the applicants). Applicants have inserted this identity language into the new claims. The use of identity ranges is well known in the art and is specifically supported by the specification at, for example, page 11, lines 21-23. Thus, one of skill in the art would recognize the ability of the G19 sequence (SEQ ID NO: 22) and the closely related G28 sequence (SEQ ID NO: 18) to produce transgenic plants with at least pathogen stress resistance or disease resistance.

The BLAST report also shows that conserved domains of G4 (SEQ ID NO: 12) with 62% identity to SEQ ID NO: 18, and G1006 (SEQ ID NO: 34) with 97% identity to SEQ ID NO: 18, and G25 (SEQ ID NO: 82) with 69% identity, show substantial sequence identity to the conserved domain of G28 (SEQ ID NO: 18) (see handwritten notes regarding % identity provided by the applicants, particularly at pages 4, 10, and 13, respectively). The BLAST analysis method is fully disclosed in the specification at page 11, lines 3-20; at page 19, lines 2-8; and at page 25, lines 32-37. In addition, the specification discloses the function and utility of

these polynucleotide and polypeptide sequences (see specification at pages 1 through 3, and pages 5 through 8, where the different polynucleotide and polypeptide sequences and their use are disclosed). Accordingly, applicants' specification, in light of this evidence, clearly demonstrates the range of polynucleotide sequences that could be used in the new methods and transgenic plants.

To further demonstrate that the functional characteristics recited in the new claims would have been understood to be present with the recited polynucleotides, and/or easily identified in transgenic plants comprising these polynucleotides, applicants also enclose a copy of Table 1 of U.S. provisional application serial no. 60/125,814, at page 46 (see Appendix D, p 45, lines 15-32; page 46, Table 1). The present application claims priority to this provisional application. Table 1 shows amino acid residues of a polypeptide sequence that may be substituted with other amino acids and are restricted to conservative substitutions.

The conserved domains of AP2-family transcription factors are more nearly identical in their sequences, with G1006 (SEQ ID NO: 34), G19 (SEQ ID NO: 22), G4 (SEQ ID NO: 12) and G25 (SEQ ID NO: 82) sharing 98%, 72%, 69%, and 72% sequence identity, respectively, with the conserved domain of G28 (please see Appendix E, showing each of these comparisons and the sequence identity). Thus, structurally and functionally related AP2 family transcription factors share a minimum of 69% sequence identity in their conserved domains, which supports new claims directed to conserved domains.

Support for claim 37 is provided by claim 1 as filed (transgenic plant comprising recombinant polynucleotide altering disease resistance or tolerance), and the specification at page 6, lines 29-31 and page 17, lines 10-23 (expression of instant AP2 transcription factors leads to enhanced tolerance to microbial, fungal, nematode or viral diseases, pathogens and pests), and by page 11, lines 21-29 (transcription factors that are homologs may share at least 40% sequence identity).

Support for claim 38 may be found in Figure 1a (conserved domain comprises residues 145-213), and the specification at page 11, lines 21-29 (transcription factors that are homologs may share at least 40% sequence identity), and on page 6, lines 4-6 ("conserved domain" refers

to a polypeptide fragment that is more conserved at a sequence level than other fragments). The specification at page 10, lines 12-26 and page 10, lines 13-14 also notes conservative substitutions, deletions, and insertions of which one of skill in the art would be aware. Further support for residues that may be substituted and with which residues they may be substituted is disclosed in Table 1 at page 46 of provisional Application serial No. 60/125,814, from which the instant application claims priority.

Support for new claim 39 is provided by the specification at, for example, page 5, line 9, and page 16, line 9 through page 17, line 24.

Support for new claim 40 is provided by claim 3 as filed and on, for example, page 3, lines 24-26, on page 13, lines 13-19, and page 14, lines 13-18.

Support for new claim 41 is provided by claim 3 as filed and on page 13, lines 15-19.

Support for new claim 42 is provided by claim 4 as filed and on page 13, lines 16-17 and page 13, line 20 through page 14, line 12.

Support for new claim 43 is provided on, for example, page 17, lines 10-11 (utility for increasing tolerance or resistance to pathogens and pests), page 6, lines 29-31 and page 17, lines 10-23 (expression of instant AP2 transcription factors leads to enhanced tolerance to, fungal, and other pathogens), on page 19, line 32 through page 21, line 28 (those genes induced after exposure to biotrophic fungal pathogens), and on page 24, line 9 to page 25, line 13 (analysis of *Arabidopsis* T2 progeny plants for pathogen resistance or pathogen tolerance).

Support for new claim 44 is provided on page 7, lines 22-28, page 17, lines 10-17, page 19, line 31 through page 21, line 28, page 24, line 9 through page 25, line 13. Statements in the specification indicating that G28 can be used to confer tolerance to fungal pathogens have been confirmed by experimentation (see description in the Heard Declaration, above and below).

Support for new claim 45 is provided by claim 5 as filed (method for altering the disease tolerance or resistance of a plant), and, for example, on page 7, line 35 (modulating a plant's response to disease), page 17, lines 10-23 (increasing tolerance or resistance to pathogens and pests), and on page 11, lines 21-29 (transcription factors that are homologs may share at least 40% sequence identity).

Support for new claim 46 is provided in Figure 1a (conserved domain comprises residues 145-213), on page 11, lines 21-29 (transcription factors that are homologs may share at least 40% sequence identity), on page 6, lines 4-6 (“conserved domain” refers to a polypeptide fragment that is more conserved at a sequence level than other fragments), page 6, lines 29-31 and page 17, lines 10-23 (expression of instant AP2 transcription factors leads to enhanced tolerance to microbial, fungal, nematode or viral diseases, pathogens and pests). The specification at page 10, lines 12-26 and page 10, lines 13-14 also notes conservative substitutions, deletions, and insertions of which one of skill in the art would be aware. Further support for residues that may be substituted and with which residues they may be substituted is disclosed in Table 1 at page 46 of provisional Application serial No. 60/125,814, from which the instant application claims priority.

Support for new claim 47 is provided by, for example, page 5, line 9, page 6, lines 28-31, and page 17, lines 10-23.

Support for new claim 48 is provided by claim 8 as filed and on, for example, page 3, lines 24-26, on page 13, lines 13-19, and page 14, lines 13-18.

Support for new claim 49 is provided by claim 8 as filed and on page 13, lines 15-19.

Support for new claim 50 is provided by claim 9 as filed and on page 13, lines 16-17 and page 13, line 20 through page 14, line 12.

Support for new claim 51 is provided on, for example, page 17, lines 10-11 (increasing tolerance or resistance to pathogens and pests), page 6, lines 29-31 and page 17, lines 10-23 (expression of instant AP2 transcription factors leads to enhanced tolerance to, fungal, and other pathogens), on page 19, lines 32 through page 21, line 28 (those genes induced after exposure to biotrophic fungal pathogens), and on page 24, line 9 to page 25, line 13 (analysis of *Arabidopsis* T2 progeny plants for pathogen resistance or pathogen tolerance).

Support for new claims 52 is provided on page 7, lines 22-28, page 17, lines 10-17, page 19, line 31 through page 21, line 28, page 24, line 9 through page 25, line 13. Statements in the specification indicating that G28 can be used to confer tolerance to fungal pathogens have been confirmed by experimentation (see description in the Heard Declaration, above and below).

Support for new claim 53 is provided by claim 10 as filed (method for altering the expression levels of at least one gene in a plant), and for example, on page 2, lines 19-23 and page 8, lines 29-34 (producing transgenic plants with modified expression levels of at least one gene), on page 17, lines 10-23 (increasing tolerance or resistance to pathogens and pests), page 6, lines 29-31 and page 17, lines 10-23 (expression of instant AP2 transcription factors leads to enhanced tolerance to microbial, fungal, nematode or viral diseases, pathogens and pests), and on page 11, lines 21-29 (transcription factors that are homologs may share at least 40% sequence identity).

Support for new claim 54 may be found in Figure 1a (conserved domain comprises residues 145-213), on page 11, lines 21-29 (transcription factors that are homologs may share at least 40% sequence identity), and on page 6, lines 4-6 ("conserved domain" refers to a polypeptide fragment that is more conserved at a sequence level than other fragments). The specification at page 10, lines 12-26 and page 10, lines 13-14 also notes conservative substitutions, deletions, and insertions of which one of skill in the art would be aware. Further support for which residues may be substituted and with which residues they may be substituted is disclosed in Table 1 at page 46 of provisional Application serial No. 60/125,814, from which the instant application claims priority.

Support for new claim 55 is provided by, for example, page 5, line 9, page 6, lines 28-31, and page 12, line 27 through page 17, line 23.

Support for new claim 56 is provided by claim 12 as filed and on, for example, page 3, lines 24-26, on page 13, lines 13-19, and page 14, lines 13-18.

Support for new claim 57 is provided by claim 12 as filed and on page 13, lines 15-19.

Support for new claim 58 is provided by claim 13 as filed and on page 13, lines 16-17 and page 13, line 20 through page 14, line 12.

Support for new claim 59 is provided on, for example, page 17, lines 10-11 (utility for increasing tolerance or resistance to pathogens and pests), page 6, lines 29-31 and page 17, lines 10-23 (expression of instant AP2 transcription factors leads to enhanced tolerance to, fungal, and other pathogens), on page 19, lines 32 through page 21, line 28 (those genes induced after

exposure to biotrophic fungal pathogens), and on page 24, line 9 to page 25, line 13 (analysis of *Arabidopsis* T2 progeny plants for pathogen resistance or pathogen tolerance).

Support for new claim 60 is provided on page 7, lines 22-28, page 17, lines 10-17, page 19, line 31 through page 21, line 28, page 24, line 9 through page 25, line 13. Statements in the specification indicating that G28 can be used to confer tolerance to fungal pathogens have been confirmed by experimentation (see description in the Heard Declaration, above and below).

Support for new claim 61 can be found in claim 1 as filed and page 6, lines 29-31 (transgenic plant comprising recombinant polynucleotide altering disease resistance or tolerance), page 17, lines 10-23 (expression of instant AP2 transcription factors leads to enhanced tolerance to microbial, fungal, nematode or viral diseases, pathogens and pests), page 11, lines 30-31 (identification of relation between two nucleic acid molecules through hybridization under stringent conditions), and on page 12, lines 1-4 (nucleic acids hybridize under stringent conditions to a probe under wash conditions of 0.2 x SSC, 0.1% SDS at 65° C).

Support for new claim 62 is provided by, for example, page 5, line 9, and page 16, line 9 through page 17, line 24.

Support for new claim 63 is provided on, for example, page 3, lines 24-26, on page 13, lines 13-19, and page 14, lines 13-18.

Support for new claim 64 is provided on page 13, lines 15-19.

Support for new claim 65 is provided on page 13, lines 16-17 and page 13, line 20 through page 14, line 12.

Support for new claim 66 is provided on, for example, page 17, lines 10-11 (increasing tolerance or resistance to pathogens and pests), page 6, lines 29-31 and page 17, lines 10-23 (expression of instant AP2 transcription factors leads to enhanced tolerance to, fungal, and other pathogens), on page 19, lines 32 through page 21, line 28 (those genes induced after exposure to biotrophic fungal pathogens), and on page 24, line 9 to page 25, line 13 (analysis of *Arabidopsis* T2 progeny plants for pathogen resistance or pathogen tolerance).

Support for new claim 67 is provided on page 7, lines 22-28, page 17, lines 10-17, page 19, line 31 through page 21, line 28, page 24, line 9 through page 25, line 13. Statements in the

specification indicating that G28 can be used to confer tolerance to fungal pathogens have been confirmed by experimentation (see description in the Heard Declaration, above and below).

Support for new claim 68 is may be found in claim 5 as filed (method for altering the disease tolerance or resistance of a plant), page 6, lines 29-31 and page 17, lines 10-23 (expression of instant AP2 transcription factors leads to enhanced tolerance to microbial, fungal, nematode or viral diseases, pathogens and pests), page 11, lines 30-31 (identification of relation between two nucleic acid molecules through hybridization under stringent conditions), and on page 12, lines 1-4 (nucleic acids hybridize under stringent conditions to a probe under wash conditions of 0.2 x SSC, 0.1% SDS at 65° C).

Support for new claim 69 is provided by, for example, page 5, line 9, page 6, lines 28-31, and page 16, line 9 through page 17, line 24.

Support for new claim 70 is provided on, for example, page 3, lines 24-26, on page 13, lines 13-19, and page 14, lines 13-18.

Support for new claim 71 is provided on page 13, lines 15-19.

Support for new claim 72 is provided on page 13, lines 16-17 and page 13, line 20 through page 14, line 12.

Support for new claim 73 is provided by claim 5 as filed (method for altering the disease tolerance or resistance of a plant) and on, for example, page 17, lines 10-11 (increasing tolerance or resistance to pathogens and pests), page 6, lines 29-31 and page 17, lines 10-23 (expression of instant AP2 transcription factors leads to enhanced tolerance to, fungal, and other pathogens), on page 19, lines 32 through page 21, line 28 (those genes induced after exposure to biotrophic fungal pathogens), and on page 24, line 9 to page 25, line 13 (analysis of *Arabidopsis* T2 progeny plants for pathogen resistance or pathogen tolerance).

Support for new claim 74 is provided on page 7, lines 22-28, page 17, lines 10-17, page 19, line 31 through page 21, line 28, page 24, line 9 through page 25, line 13. Statements in the specification indicating that G28 can be used to confer tolerance to fungal pathogens have been confirmed by experimentation (see description in the Heard Declaration, above and below).

Support for new claim 75 may be found at, for example, page 17, lines 10-11 (utility for increasing tolerance or resistance to pathogens and pests), page 6, lines 29-31 and page 17, lines

10-23 (expression of instant AP2 transcription factors leads to enhanced tolerance to, fungal, and other pathogens), on page 19, line 32 through page 21, line 28 (those genes induced after exposure to biotrophic fungal pathogens), and on page 24, line 9 to page 25, line 13 (analysis of *Arabidopsis* T2 progeny plants for pathogen resistance or pathogen tolerance). The specification at page 10, lines 13-14 also notes conservative substitutions, deletions, and insertions of which one of skill in the art would be aware. Further support for residues that may be substituted and with which residues they may be substituted is disclosed in Table 1 at page 46 of provisional Application serial No. 60/125,814, from which the instant application claims priority.

Support for new claim 76 is provided on page 7, lines 22-28, page 17, lines 10-17, page 19, line 31 through page 21, line 28, page 24, line 9 through page 25, line 13. Statements in the specification indicating that G28 can be used to confer tolerance to fungal pathogens have been confirmed by experimentation (see description in the Heard Declaration, above and below).

RESPONSE TO REJECTIONS

Response to Rejection under 35 U.S.C. § 112, second paragraph

Claims 17-36 were rejected under 35 U.S.C. § 112, second paragraph, as they allegedly failed to particularly point out and distinctly claim the subject matter regarded as the invention. Applicants respectfully disagree.

Each of claims 17-36 have been canceled without prejudice or disclaimer and not for reasons of patentability. However, applicants submit that one of skill in the art would understand the metes and bounds of these claims. For example, the “conserved domain” of a transcription factor is a well-known concept in the field. Furthermore, the specification and the priority document specifically lists the conserved domains for a large number of transcription factors (see Table 1). Furthermore, that the conserved domains of transcription factors can be localization domains, activation domains, and DNA binding domains, for example, is also well known in the art. Applicants included a number of citations to references discussing the transcription factor families (see page 8, for example), and these and other references demonstrate that one of skill in

the art would understand the metes and bounds of each of the terms noted by the Examiner at page 5 of Paper No. 19.

The new claims 37-76 for the presently claimed transcription factors refer to only SEQ ID NO: 17 or 18 and are directed to a specific, defined conserved domain of residues 145-213 of SEQ ID NO: 18 which is supported by the specification as filed (see Figure 1a). That the conserved domains of transcription factors can be localization domains, activation domains, and DNA binding domains, for example, is also well known in the art. Applicants included a number of citations to references discussing the transcription factor families (*see* page 8, for example), and these and other references demonstrate that one of skill in the art would understand the metes and bounds of each of the terms noted by the Examiner at page 5 of Paper No. 19.

Applicants also submit that it would be abundantly clear to one of skill in the art what is meant by the term "conserved domain" in the present context. For example, the "conserved domain" of a transcription factor is a well-known concept in the field. See for example, Riechmann and Meyerowitz (1998), which is incorporated by reference (page 7, line 37 to page 8, line 1, and page 26, lines 29-30; submitted by Applicants in Information Disclosure Statement 11th October, 2002), and which defines conserved AP2 domains, with reference to, for example, the "conserved AP2 DNA-binding domain" (page 634, column 2, line 6); and "the conserved AP2 domain" (page 641, column 2, line 13). One of skill in the art would also be aware that the term "conserved domain" is often used in the art. For example, a search of issued U.S. patents yielded a sizeable number of references that make use of the term "conserved domain" (from 1996-2002 a search of ("conserved domain" AND sequence) revealed 338 patents that use the term in the present context).

The claims that were directed to "freezing, or nutrient, or pathogen stress" have been canceled, and the new claims are directed to "disease tolerance or resistance" or "tolerance to fungal disease", which are art-recognized terms and are defined in the specification; for example, page 7, lines 12-18, states: "[o]f particular interest are traits relating to increased disease resistance or tolerance of a plant, such as alterations in cell wall composition, trichome number or structure, callose induction, phytoalexin induction, alterations in the cell death response or the

like. These transgenic plants may be more resistant to biotrophic or necrotrophic pathogens such as a fungus, bacterium, mollicute, virus, nematode, a parasitic higher plant or the like and associated diseases. Another desirable phenotype is a change in the overall gene expression pattern of the plant in response to disease"). Page 17, lines 14-23 list pathogens and pests to which the plants can become tolerant.

Regarding the rejection based on improper Markush format, Applicant's believe the new claims avoid the rejection. The same may be said for the rejection based on indefiniteness of claims 22, 27 and 33, which referred to amino acid sequences, and claims that were dependent on indefinite claims.

The new claims make no reference to "DNA-binding domains." Therefore, even though one of skill in the art would clearly understand this term and its meaning, applicants need not address this reason for the rejection here.

Applicants submit that the new claims satisfy the requirements of 35 U.S.C. § 112, second paragraph, and respectfully request that this rejection be withdrawn.

Response to Rejection under 35 U.S.C. § 112, first paragraph

Claims 17-36 were rejected under 35 U.S.C. § 112, first paragraph, as the specification allegedly fails to reasonably convey that Applicants had possession of the invention. Applicants respectfully disagree with this rejection.

At page 6 of Paper No. 19, the Examiner characterizes the transcription factor of SEQ ID NO: 17 and 18 as "putative." Applicants respectfully but strongly disagree, as all the available and pertinent evidence indicates that SEQ ID NO: 17 encodes, and SEQ ID NO: 18 represents, a transcription factor, for at the very least the following reasons.

Applicants respectfully submit that the Examiner may not fully appreciate the PTO Written Description Examination Guidelines as they apply here. The USPTO Written Description Examination Guidelines state that:

(t)he written description requirement for a claimed genus may satisfied through sufficient description of a representative number of species by actual reduction to practice ..., reduction to drawings ..., or by disclosure of relevant, identifying characteristics, i.e.,

structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show the applicant was in possession of the claimed genus. (Federal Register, Jan. 5, 2001, Vol. 66(4) page 1106, II § 3 (a)(2).)

As shown in the attached report (Appendix F) and the Heard Declaration (Appendix C), Applicants correctly predicted the function of the sequence G28 (SEQ ID NO: 17; encoding SEQ ID NO: 18) based upon the identification of the sequence as an AP2 transcription factor and upon results from microarray experiments as disclosed in the instant application, and therefore Applicants characterized the sequence (G28) structurally and functionally. This is reflected by the present specification, which asserts in no uncertain terms that G28 is a transcription factor. See for example, page 4, line 30 through page 5, line 10: The transcription factor sequence may comprise a whole coding sequence or a fragment or domain of a coding sequence. A "fragment or domain, as referred to polypeptides, may be a portion of a polypeptide which performs at least one biological function of the intact polypeptide in substantially the same manner or to a similar extent as does the intact polypeptide. ... Exemplary polynucleotides or polypeptides comprise a sequence provided in the Sequence Listing as ... SEQ ID No.17 (G28), SEQ ID No.18 (G28 protein)." Applicants also clearly assert that G28 is a transcription factor in the specification at Figure 1a, because they assign a transcription factor family name (AP2) to the sequence.

Furthermore, as Fujimoto *et al.* ((2000) Plant Cell 12: 393-404, attached) point out, G28 (AtERF1; GenBank accession number AB008103) and related molecules are "members of a novel family of transcription factors that are specific to plants" (Abstract, lines 1-2). AtERF1 expression was also induced by ethylene and wounding, but not by other abiotic stresses such as cold, salinity, or drought (Fujimoto *et al.*, (2000), *supra*). Biotic stresses were apparently not tested. Since Fujimoto *et al.* published data identifying G28 as a transcription factor, they provide further evidence that Applicants were correct when they identified G28 as a transcription factor.

Furthermore, as Riechmann and Meyerowitz (1998) *supra*, point out "[f]ive amino acid residues are absolutely conserved among all of the AP2 domain sequences...[t]he conservation of those residues suggests their importance for the structure/function of the AP2 domain") p. 635,

column 2, lines 41-47). The sequence of G28 (SEQ ID NO: 18) with the five absolutely conserved residues shown in boldface in the underlined conserved domain below, are:

MSMTADSQSDYAFLESIRRHLLESEPILESTASSVTQSCVTGQS~~IKPVYGRNPSFSKLYPCFTESWGDL~~
PLKENDSEDMVYGLND~~AFHGGWEPS~~SSSSDEDRSSFPSVKIETPESFAAVDSVPVKKEKTSPVSAAVTA
AKGKHYR**G**VRQRPW**G**KFAAEIRDPAKNGARVWLGT~~FETAEDAALAY~~**DRAAFRMR****G**SR~~ALL~~**N**FPLRVNSG
EPDPVRIKSKRSSFSSSNENGAPKKRTVAAGGGMDKGLTVKCEVVEVARGDRLLVL

As noted in the Riechmann reference on page 635, column 2, lines 3-7, "[a] large number of sequences encoding AP2/EREBP proteins are already present in the databases and can be *easily identified* through BLAST searches due to the conservation of the AP2 domain, which, as mentioned above, is the only region conserved among all the proteins of the family (*emphasis added*)."¹ Thus, one of skill in the art would not doubt that G28, having an AP2 conserved domain, and possessing the prerequisite five amino acid residues that are conserved among all of the AP2 domain sequences, is a member of the AP2 family of transcription factors.

Finally, and perhaps most significantly, Applicants have demonstrated the function of G28 as a transcription factor. In the declaration under 37 C.F.R. § 1.132 from Dr. Jacqueline Heard (Appendix C), who is a listed inventor of the instant application, Dr. Heard submits results of experiments performed prior to the date of filing the instant application. The results are presented as tables which show that Applicants had identified numerous polynucleotide sequences which endogenous mRNA levels were up-regulated by pathogens and/or methyl jasmonate, including G28 (SEQ ID NO: 17), G4 (SEQ ID NO: 12), G19 (SEQ ID NO: 22), G1006 (SEQ ID NO: 34), and G25 (SEQ ID NO: 82). Dr Heard also submits an internal report which discloses the effect of overexpressing G28 (SEQ ID NO: 17) in a transgenic plant. The report shows that Applicants' SEQ ID NO: 17 (and hence the encoded SEQ ID NO: 18) confers tolerance to fungal pathogens, just as the G19 (SEQ ID NO: 22) sequence noted above does.

Thus, the knowledge in the art, the above-described disclosures from the specification defining G28 as a transcription factor, coupled with the data submitted, all point to the same conclusion: G28 is a transcription factor.

With regard to the statement in Paper 19 that "Applicant's definition of a 'conserved domain' appears to be relative to SEQ ID NO: 18," Applicants note that the new claims are now directed to transcription factors comprising a conserved domain of a plant AP2 transcription factor wherein the conserved domain comprises one of an amino acid sequence of residues 145-213 of SEQ ID NO: 18, or an amino acid sequence having at least 84% identity to residues 145-213 of SEQ ID NO: 18, or an amino acid sequence of residues 145-213 of SEQ ID NO: 18 having one or more conservative substitutions, deletions, or insertions.

Applicants clearly identified amino acid residues 145-213 of SEQ ID NO: 18 at Figure 1a. The specification on page 11, lines 21-22 points out that "transcription factors that are homologs of the disclosed sequences will typically share at least 40% amino acid sequence identity," and page 6, lines 4-6: "[a] 'conserved domain' refers to a polynucleotide or polypeptide fragment that is more conserved at a sequence level than other fragments when the polynucleotide or polypeptide is compared with homologous genes or proteins from other plants."

The specification at page 10, lines 13-14 also notes the conservative substitutions, deletions, and insertions of which one of skill in the art would be aware. Support for which residues may be substituted and which residues they may be substituted with, is further disclosed in Table 1 at page 46 of provisional Application serial No. 60/125,814 (Appendix D), from which the instant application claims priority. In addition, fragments of domains of transcription factor sequences are specifically disclosed at page 4, lines 32-37, and in Figure 1.

Applicants also note that SEQ ID NO: 22 (G19) is disclosed in the specification as being significantly induced upon infection by the fungal pathogen *Erysiphe orontii* (see specification at page 25, lines 4-9). As shown in the accompanying BLAST report (Appendix F), G19 and G22 share 42% identity (note that the specification discloses that transcription factors that are homologs will typically share at least 40% amino acid sequence identity (page 11, lines 21-22)). The conserved domain of G28 (SEQ ID NO: 18) shows even greater sequence identity to G19 (SEQ ID NO: 22), namely 66% identity (see attached BLAST report, page 11; handwritten notes regarding % identity). Thus, the BLAST report supports the new claims directed to an amino acid sequence having at least 42% identity to SEQ ID NO: 18. The use of identity ranges is well

known in the art and is specifically supported by the specification at, for example, page 11, lines 21-23. Thus, one of skill in the art would recognize the ability of the G19 sequence (SEQ ID NO: 22) and the closely related G28 sequence (SEQ ID NO: 18) to produce transgenic plants with disease tolerance or resistance, as is documented by Dr. Heard (see attached Declaration under 37 CFR 1.132, paragraphs 8 and 9 in particular).

The BLAST report also shows that conserved domains of G4 (SEQ ID NO: 12) with 62% identity to SEQ ID NO: 18, and G1006 (SEQ ID NO: 34) with 97% identity to SEQ ID NO: 18, and G25 (SEQ ID NO: 82) with 69% identity, show substantial sequence identity to the conserved domain of G28 (SEQ ID NO: 18) (see handwritten notes regarding % identity provided by the Applicants, particularly at pages 4, 10, and 13, respectively). The BLAST analysis method is fully disclosed in the specification at page 11, lines 3-20; at page 19, lines 2-8; and at page 25, lines 32-37. In addition, the specification discloses the function and utility of these polynucleotide and polypeptide sequences (see specification at pages 1 through 3, and pages 5 through 8, where the different polynucleotide and polypeptide sequences and their use are disclosed). Accordingly, Applicants' specification, in light of this evidence, clearly demonstrates the range of polynucleotide sequences that could be used in the new methods and transgenic plants.

As one of ordinary skill in the art recognizes, conserved domains may be identified as regions or domains of identity to a specific consensus sequence (see, for example, Riechmann et al., (2000) *Science* 290: 2105-2110; reference attached). Thus, by using alignment methods well known in the art, the conserved domains of the AP2 (APETALA2) domain transcription factor, the function of the presently claimed transcription factors may be determined family. Please see, for example, Riechmann and Meyerowitz (1998) *Biol. Chem.* 379: 633-646, which is incorporated by reference at page 7, line 37, continuing to page 8, line 1 of the specification (submitted by Applicants in Information Disclosure Statement 11th October, 2002). Riechmann and Meyerowitz specifically note:

(1) "Five amino acid residues are absolutely conserved among all of the AP2 domain sequences...[t]he conservation of those residues suggests their importance for the structure/function of the AP2 domain") p. 635, column 2, lines 41-47);

(2) "[a] primary source of specificity will be found to have very related, if not identical, DNA-binding specificities, similar to what has been observed for other large families of transcription factors" p. 643, column 1, lines 12-16; and

(4) "[p]artial genetic redundancy for AP2 function and/or postranscriptional mechanisms of control of AP2 activity may underlie" (p. 640, column 2, lines 32-35).

Thus, at the time the present application was filed, one of skill in the art would recognize that portions of the AP2 domain are *absolutely conserved*, which strongly suggests their importance in imparting function and functional overlap, and that AP2 transcription factors are distinguishable by differential DNA-binding specificities, which are likely to be related, if not identical, within the family, and that there is genetic redundancy for AP2 function. One of skill in the art would instantly recognize that data obtained with G19-overexpressing plants would lead to the prediction that similar results would be obtained with plants overexpressing a transcription factor gene with a highly similar AP2 domain, as indicated in the present application.

Based on these published assertions, one of skill in the art would clearly have recognized from the knowledge available in the art, and from Applicants' specification and Figures, that G28 is a transcription factor and has the "only region conserved among all the proteins of the family" (see reference to Riechmann (1998), above), where conserved domains are listed for numerous sequences including SEQ ID NO: 18. Accordingly, Applicants' adequately demonstrated that they possessed sequences comprising a conserved domain as claimed. One of skill in the art could clearly perform the BLAST searches in order to print out and physically possess the sequences having at least 84% identity to the conserved domain of SEQ ID NO: 18, as recited in the new claims. In view of these facts, the art-recognized use of the terms "transcription factor" and "conserved domain," and the definition of a conserved AP2 domain (see above), Applicants submit that the new claims satisfy the written description requirement of 35 U.S.C. § 112, first paragraph.

To further demonstrate that the functional characteristics recited in the new claims would have been understood to be present with the recited polynucleotides, or easily identified in

transgenic plants comprising these polynucleotides, Applicants also enclose a copy of Table 1 of U.S. provisional application serial no. 60/125,814, at page 46 (Appendix D). The present application claims priority to this provisional application. Table 1 shows amino acid residues of a polypeptide sequence that may be substituted with other amino acids and are restricted to conservative substitutions.

Accordingly, one of skill in the art would not doubt that Applicants have adequately described the recited polynucleotides, specified a novel and useful transcription factor function of G28 and other AP2 family transcription factors in plants, and demonstrated that they can be made and used to enhance plant disease tolerance, for example, or that transgenic plants as claimed can be made and used. Applicants respectfully request reconsideration and withdrawal of the rejection.

Accordingly, applicants submit that the new claims satisfy the written description requirement of 35 U.S.C. § 112, first paragraph.

Claims 17-36 were further rejected under 35 U.S.C. § 112, first paragraph, as the specification allegedly failed to describe the subject matter of the claims in such a way as to enable one of skill in the art to make and use it. Applicants respectfully disagree.

The Examiner asserts that Applicants' specification fails to teach how SEQ ID NO: 18 can enhance a plant tolerance to stresses from pathogens, disease, freezing, etc. (*see* page 8 of Paper No: 19). The new claims are not directed to disease and freezing stress. As noted above, Dr. Heard has submitted that Applicants have in their possession data showing that SEQ ID NO: 17 confers pathogen or disease tolerance (*see* attached Declaration Appendix C, at exhibit H). One of skill in the art would not doubt these data. Applicants respectfully request reconsideration.

The Examiner has also asserted that the Quattrocchio document implies that undue experimentation would be required to produce a desired phenotype (*see* page 9 of Paper No. 19). First, the experiments disclosed in the specification at page 20, lines 11-16, and at page 24, lines 11-37 and continued on page 25, lines 1-2, show how one of skill in the art can determine the

plant traits as recited in the claims. These are the same types of experiments used to produce the results in the report for the G28 sequence.

Second, a careful reading of Quattrocchio shows that it does not support the undue experimentation position. Quattrocchio discusses the *Petunia an2* gene, encoding a MYB-domain containing protein and that it had been suggested it could be the ortholog of the *Zea mays c1* gene (Quattrocchio, page 476, first column, second paragraph, lines 2-5). The *an2* gene had previously been shown to regulate anthocyanin biosynthesis (see Quattrocchio, page 478, first column, lines 1-2). Quattrocchio further states that “[t]he evolutionary model *predicts* that expression of *c1* and *an r* gene in *P. hybrida* induces *dfrA* but not *chsA*, *which was confirmed* ...” and that “[t]he model also *predicts* that *AN2* (the protein encoded by the *an2* gene) should activate both early and late anthocyanin genes in *Z. mays*. *This is precisely what we observed experimentally*” (see Quattrocchio, page 486, first column, first paragraph, lines 5-10; *emphasis added*). Thus, Quattrocchio shows that the MYB-encoding polynucleotide/genes *an2* and *c1* are functionally interchangeable between different plant species and that the same pathway of genes is controlled by the orthologous MYB-domain containing protein.

This interchangeability is further supported by Quattrocchio’s statement that “[o]ur data for *P. hybrida* show that neither the *Z. mays* regulators *c1* and *lc* ... nor *an2* and *jaf13* from *P. hybrida* can activate the early flavonoid genes” Therefore, the orthologous MYB-encoding polynucleotide sequences do not activate transcription inappropriately under the experimental conditions observed (see Quattrocchio, page 486, first column, fourth paragraph, lines 3-5 and continued in second column, line 1).

Nowhere does Quattrocchio suggest that the effect of transforming a plant with a heterologous “MYB” encoding polynucleotide “is unpredictable.” In fact, Quattrocchio strongly suggests the very opposite, that transforming a plant with a heterologous MYB-encoding polynucleotide results in a predictable effect on the **same** pathway.

Also, Dr. Heard addresses the understanding one of skill in the art has for the contents of Quattrocchio in her declaration (see page 4, in particular). Dr. Heard explains that the Quattrocchio document actually supports the predictable nature of using transcription factors to produce predictable effects on the same traits in plants. Further, the Duggleby (of record) and

Quattrocchio documents together, as discussed at pages 3-4 of the declaration, provide additional evidence of the ability of one of skill in the art to use the sequences recited in the claims. These statements demonstrate that the conclusions the Patent Office asserts from the Quattrocchio document are incorrect.

Accordingly, Applicants respectfully request reconsideration of the Quattrocchio document and this rejection.

Applicants also submit that a *prima facie* case of lack of enablement has not been made.

The remaining arguments are directed to the "homologous window sequence" recitation. Applicants note that the new claims do not recite the "homologous window sequence" discussed in this rejection. Accordingly, Applicants respectfully request reconsideration and that the Examiner withdraw the rejection.

Response to Rejection under 35 U.S.C. § 102

Claims 17-36 were rejected under 35 U.S.C. § 102(b) as being anticipated by Martin *et al.* (WO 97/47183).

Applicants note that the new claims do not recite a "homologous window sequence" or the "at least 6 consecutive amino acids" discussed in this rejection. Furthermore, the SEQ ID NO: 4 of Martin does not display the sequence identity to amino acid residues 145-213 of SEQ ID NO: 18 now recited in the claims. Accordingly, Applicants believe there is no anticipation of the present claims by the Martin reference.

Applicants respectfully request reconsideration and withdrawal of this rejection.

Provisional Double Patenting Rejection


The Examiner has rejected Claims 17-36 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over copending applications 09/713,994 and 09/934,455.

As this is a provisional rejection, Applicants will address this rejection when claims of this or the copending application are allowed.

Applicants have requested an extension of time of two months in order to respond to the outstanding Office Action. No additional extension of time fees or requests for extension of time, or any other fees or petitions, are believed to be necessary to enter and consider this paper. If, however, any petitions or extensions of time are required or any fees are due in order to enter or consider this paper or enter or consider any paper accompanying this paper, including fees for net addition of claims, or in order to keep this application pending, Applicants hereby request any extensions or petitions necessary and the Commissioner is hereby authorized to charge Deposit Account No. 50-1129 for any fees.

Respectfully submitted,
WILEY REIN & FIELDING LLP

Date: October 29, 2002

By: 
David J. Kulik
Registration No. 36,576

Enclosures: Appendix A (Marked-up version of amended Specification pages – 2 pages)
Appendix B (Gene Expression data; G1006 and G25 – 1 page)
Appendix C (executed declaration of Dr. Heard, pages 1-5 and Exhibits A-G)
Appendix D (pages 45 and 46 of priority application 60/125,814)
Appendix E (2 page conserved domain sequence comparison data for G28, G4, G19, G25, and G1006)
Appendix F (14 page BLAST report for G28, with handwritten notes)\
and
Fujimoto *et al.*, The Plant Cell 12:393-404 (2000)
Riechmann *et al.*, Science 290:2105-2110 (2000)

Wiley Rein & Fielding LLP
Attn: Patent Administration
1776 K Street, N.W.
Washington, D.C. 20006
202.719.7000 (Telephone)
202.719.7049 (Facsimile)



APPENDIX A



PATENT
Application No. 09/533,029
Atty Docket No. MBI-0010

APPENDIX A

Marked-up Version of Amended Specification at pages 7-8

These transcription factors can be used to modulate a plant's response to disease. The plant transcription factors may belong to one of the following transcription factor families: the AP2 (APETALA2) domain transcription factor family (Riechmann and Meyerowitz (1998) [J.] Biol. Chem. 379:633-646); the MYB transcription factor family (Martin and Paz-Ares, (1997) Trends Genet. 13:67-73); the MADS domain transcription factor family (Riechmann and Meyerowitz (1997) [J.] Biol. Chem. 378:1079-1101); the WRKY protein family (Ishiguro and Nakamura (1994) Mol. Gen. Genet. 244:563-571); the ankyrin-repeat protein family (Zhang et al. (1992) Plant Cell 4:1575-1588); the zinc finger protein (Z) family (Klug and Schwabe (1995) FASEB J. 9: 597-604); the homeobox (HB) protein family (Buerglin, in: Duboule (1994) Guidebook to the Homeobox Genes, Oxford University Press, pp. 27-71); the CAAT-element binding proteins (Forsburg and Guarente (1989) Genes Dev. 3:1166-1178); the squamosa promoter binding proteins (SPB) (Klein et al. (1996) Mol. Gen. Genet. 1996 250:7-16); the NAM protein family (Souer et al. (1996) Cell 85:159-170); the IAA/AUX proteins (Rouse et al. (1998) Science 279:1371-1373); the HLH/MYC protein family (Littlewood et al. (1994) Prot. Profile 1:639-709); the DNA-binding protein (DBP) family (Tucker et al. (1994) EMBO J. 13:2994-3002); the bZIP family of transcription factors (Foster et al. (1994) FASEB J. 8:192-200); the Box P-binding protein (the BPF-1) family (da Costa e Silva et al. (1993) Plant J. 4:125-135); the high mobility group (HMG) family (Bustin and Reeves (1996) Prog. Nucl. Acids Res. Mol. Biol. 54:35-100); the scarecrow (SCR) family (Di Laurenzio et al. (1996) Cell 86:423-433); the GF14 family (Wu et al. (1997) Plant Physiol. 114:1421-1431); the polycomb (PCOMB) family (Kennison (1995) Annu. Rev. Genet. 29:289-303); the teosinte branched (TEO) family (Luo et al. (1996) Nature 383:794-799; the ABI3 family (Giraudat et al. (1992) Plant Cell 4:1251-1261); the triple helix (TH) family (Dehesh et al. (1990) Science 250:1397-1399); the EIL family (Chao et al. (1997) Cell 89:1133-44); the AT-HOOK family (Reeves and Nissen (1990) Journal of Biological Chemistry 265:8573-8582); the S1FA family (Zhou et al. (1995) Nucleic Acids Res. 23:1165-1169); the bZIPT2 family (Lu and Ferl (1995) Plant Physiol. 109:723); the YABBY

family (Bowman et al. (1999) *Development* 126:2387-96); the PAZ family (Bohmert et al. (1998) *EMBO J.* 17:170-80); a family of miscellaneous (MISC) transcription factors including the DPBF family (Kim et al. (1997) *Plant J.* 11:1237-1251) and the SPF1 family (Ishiguro and Nakamura (1994) *Mol. Gen. Genet.* 244:563-571); the golden (GLD) family (Hall et al. (1998) *Plant Cell* 10:925-936).

WRFMAIN 1184985.1

APPENDIX B

Appendix B


G1006

Gene Expression in Different Conditions

Auxin (soil)	ABA (soil)	Cold (soil)	Heat (soil)	Salt (soil)	Drought (soil)	Osmotic (soil)	Control (soil)	Erysiphe (soil)	Fusarium (plate)	SA (plate)	Control (plate)
-----------------	---------------	----------------	----------------	----------------	-------------------	-------------------	-------------------	--------------------	---------------------	---------------	--------------------

L	L	L	L	L	L	L	L	L	L	L	L
---	---	---	---	---	---	---	---	---	---	---	---

PCR: 27 CYCLE



↑	↑	↑	↑
Control (in soil)	Erysiphe (in soil)	Fusarium (on plate)	Control (on plate)

G25

Gene Expression in Different Conditions

Auxin (soil)	ABA (soil)	Cold (soil)	Heat (soil)	Salt (soil)	Drought (soil)	Osmotic (soil)	Control (soil)	Erysiphe (soil)	Fusarium (plate)	SA (plate)	Control (plate)
-----------------	---------------	----------------	----------------	----------------	-------------------	-------------------	-------------------	--------------------	---------------------	---------------	--------------------

H	H	L	L	L	L	L	L	L	H	H	L
---	---	---	---	---	---	---	---	---	---	---	---

PCR: 33 CYCLE



↑	↑
Fusarium (on plate)	Control (on plate)



APPENDIX C

Executed Declaration of Jacqueline E. Heard Under 37 CFR 1.132

Exhibit A: *Fusarium* treatment after 24 hours

Exhibit B: *Fusarium* treatment after 48 hours

Exhibit C: *Erysiphe* treatment after 7 days

Exhibit D: Methyl Jasmonate treatment after 24 hours

Exhibit E: *Botrytis* treatment after 12 hours

Exhibit F: *Erysiphe* treatment

Exhibit G: Methyl Jasmonate treatment

Exhibit H: Summary of Overexpressor G28, Family AP2

APPENDIX D

Appendix D

share at least 50%, 90% or 95% sequence identity. The homologs will also have substantially the same DNA binding specificity. At the nucleotide level, the sequences will typically share at least 40% nucleotide sequence identity, preferably at least 50%, 60%, 70% or 80% sequence identity, and more preferably 85%, 90%, 95% or 97% sequence identity.

Homologs from the same plant, different plant species or other organisms may be identified using sequence alignment methods and homology calculations, such as those described in Altschul et al. (1994) *Nature Genetics* 6: 119-129. For example, the NCBI Basic Local Alignment Search Tool (BLAST) (Altschul et al. (1990) Basic local alignment search tool. *J. Mol. Biol.* 215:403-410), is available from several sources, including the National Center for Biotechnology Information (NCBI), Bethesda, MD, for use in connection with the sequence analysis programs blastp, blastn, blastx, tblastp, tblastn and tblastx.

Substitutions, deletions and insertions introduced in the DNA binding domain are also envisioned by this invention. Amino acid substitutions are typically of single residues; insertions usually will be on the order of about from 1 to 10 amino acid residues; and deletions will range about from 1 to 30 residues. Deletions or insertions preferably are made in adjacent pairs, i.e., a deletion of two residues or insertion of two residues. Substitutions, deletions, insertions or any combination thereof may be combined to arrive at a final construct. Obviously, the mutations that are made in the DNA encoding the protein must not place the sequence out of reading frame and preferably will not create complementary regions that could produce secondary mRNA structure.

Substitutional variants are those in which at least one residue in the amino acid sequence has been removed and a different residue inserted in its place. Such substitutions generally are made in accordance with the following Table 1 when it is desired to finely modulate the characteristics of the protein. Table 1 shows amino acids which may be substituted for an original amino acid in a protein and which are typically regarded as conservative substitutions.

Table 1

Original Residue	Conservative Substitutions
Ala	ser
Arg	lys
Asn	gln; his
Asp	glu
Cys	ser
Gln	asn
Glu	asp
Gly	pro
His	asn; gln
Ile	leu, val
Leu	ile; val
Lys	arg; gln; glu
Met	leu; ile
Phe	met; leu; tyr
Ser	thr
Thr	ser
Trp	tyr
Tyr	trp; phe
Val	ile; leu

An alternative indication is to show whether two nucleic acid molecules are closely related is that the two molecules hybridize to each other under stringent conditions. Stringent conditions are sequence dependent and are different under different environmental parameters. Generally, stringent conditions are selected to be about 5°C to 20°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. Conditions for nucleic acid hybridization and calculation of stringencies can be found in Sambrook et al., Molecular Cloning. A Laboratory Manual, Ed. 2, Cold Spring Harbor Laboratory Press, New York (1989) and Tijssen (1993) *Laboratory Techniques in Biochemistry and Molecular Biology--Hybridization with Nucleic Acid Probes* Part I, Chapter 2 "Overview of principles of hybridization and the strategy of nucleic acid probe assays", Elsevier, New York (1993). Nucleic acid molecules that hybridize under stringent conditions will typically hybridize to a probe based on either the entire cDNA

APPENDIX E

Appendix E

Percent identity comparisons of conserved domains (underlined) of subject sequences of AP2 transcription factor family members as disclosed in specification USSN 09/533,029.

SEQ ID NO:18 (G28) (query sequence) Conserved domain = residues 145-213
MSMTADSQSDYAFLESIRRHLLGESEPILESTASSVTQSCVTGQS~~IKPVYGRNPSFSKLYPCFTESWGDPLKEND~~
SEDMLVYGI~~LNDAFHGGWEPSSSSDEDRSSFP~~SVKIETPESFAAVD~~SPVKEKT~~SPVSAAVTA~~AKGKHYRGVRQR~~
PWGKFAAE~~IRDPAKNGARVWLGT~~FETAEDAALAYDRAA~~FRMRGS~~RALLNFPLRVNS~~GE~~PD~~PVRI~~KS~~KRSS~~F~~SSN~~EN
GAPKKRRTVAAGGGMDKGLTVKCEVVEARGDRLLV

BLAST comparisons of subject sequences disclosed in specification USSN 09/533,029

SEQ ID NO:12 (G4) Conserved domain = residues 121-188
MCGGAIISDFIPPPRSLRV~~TNEF~~IPDLK~~NKV~~KASKRSNKR~~SDF~~DL~~DD~~FEAD~~FQG~~FK~~DD~~SAFD~~CED~~DDDV~~F~~V~~N~~V
KPFVFTATT~~KPV~~ASAFV~~STV~~GSAYAKKT~~VES~~AEQA~~EK~~SSKRKR~~KN~~QYRG~~I~~R~~Q~~R~~P~~WG~~K~~WAAE~~I~~R~~D~~PR~~K~~GS~~R~~E~~WL~~GT~~FD~~
~~TAA~~EEA~~RAY~~AA~~R~~RI~~G~~T~~K~~A~~V~~N~~F~~PEEK~~N~~PSV~~S~~Q~~K~~R~~P~~SA~~K~~T~~NN~~LQ~~K~~S~~V~~A~~K~~P~~N~~K~~S~~V~~T~~L~~V~~QQ~~P~~TH~~L~~S~~Q~~Q~~Y~~C~~N~~N~~F~~DN
SF~~G~~DMS~~F~~MEE~~K~~PQ~~M~~YNNQ~~F~~GL~~T~~N~~S~~FDAGG~~N~~NG~~Y~~Q~~Y~~F~~S~~SDQ~~G~~S~~N~~F~~D~~C~~E~~FG~~W~~SD~~H~~G~~P~~K~~T~~PE~~I~~S~~M~~LV~~N~~NE~~A~~F~~V~~E
TNA~~A~~KKL~~K~~P~~N~~S~~E~~SD~~D~~DL~~M~~AYLD~~N~~ALWD~~T~~PL~~E~~VEAMLGADAGAVT~~Q~~EE~~E~~NP~~V~~EL~~W~~SL~~D~~E~~I~~FM~~L~~EG~~D~~F

SEQ ID NO:12 (G4) (Amino Acid Sequence) (gf=1)

Length = 375

Score = 90.5 bits (223), Expect = 1e-20

Identities = 43/62 (69%), Positives = 52/62 (83%), Gaps = 1/62 (1%)

Query: 4 YRGVRQR~~P~~WGKFAAE~~I~~R~~D~~PAKNGARVWLGT~~F~~ETAEDAALAYDRAA~~FR~~MRGS~~R~~ALLNFPLR 63
YRG+RQR~~P~~WGK+AAE~~I~~R~~D~~P K G+R WLGT~~F~~+TAE+AA AYD AA R+RG++A +NFP
Sbjct: 124 YRGIRQR~~P~~WGK~~W~~AAE~~I~~R~~D~~PR~~K~~-GS~~R~~E~~WL~~GT~~F~~D~~T~~AA~~E~~AR~~A~~RAYDAA~~R~~RI~~G~~T~~K~~A~~V~~N~~F~~PEE 182

Query: 64 VN 65

N

Sbjct: 183 KN 184

SEQ ID NO:22 (G19) Conserved domain = residues 76-145

MCGGAIISDYAPLVT~~K~~A~~K~~GR~~K~~L~~T~~AEEL~~W~~SELD~~A~~ADD~~F~~WG~~F~~Y~~S~~TS~~K~~L~~H~~PT~~N~~Q~~V~~N~~V~~KEEAV~~K~~KEQ~~A~~TE~~P~~G~~K~~R~~R~~K~~R~~
VYRG~~I~~R~~K~~RP~~W~~G~~K~~WAAE~~I~~R~~D~~PR~~K~~G~~V~~R~~V~~WLGT~~F~~NT~~A~~EE~~A~~AMAYD~~V~~A~~A~~K~~Q~~I~~R~~G~~D~~K~~A~~LN~~F~~PD~~L~~H~~H~~PPP~~P~~NY~~T~~PPP~~S~~PR~~S~~
TDQ~~P~~PA~~K~~K~~V~~CV~~V~~SQ~~E~~SEL~~S~~Q~~P~~S~~F~~P~~V~~E~~C~~I~~G~~F~~G~~N~~G~~DEF~~Q~~N~~L~~S~~Y~~G~~F~~E~~P~~D~~Y~~DL~~K~~QQ~~I~~SS~~L~~E~~S~~F~~L~~E~~D~~G~~N~~TAE~~Q~~P~~S~~QL~~D~~E~~S~~
V~~S~~E~~V~~D~~M~~W~~M~~L~~DD~~V~~I~~AS~~Y~~E

SEQ ID NO:22 (G19) (Amino Acid Sequence) (gf=1)

Length = 248

Score = 89.7 bits (221), Expect = 2e-20

Identities = 42/58 (72%), Positives = 50/58 (85%), Gaps = 1/58 (1%)

Query: 4 YRGVRQR~~P~~WGKFAAE~~I~~R~~D~~PAKNGARVWLGT~~F~~ETAEDAALAYDRAA~~FR~~MRGS~~R~~ALLNFP 61
YRG+R+R~~P~~WGK+AAE~~I~~R~~D~~P K G RVWLGT~~F~~ TAE+AA+AYD AA ++RG +A LNFP
Sbjct: 79 YRGIRKR~~P~~WGK~~W~~AAE~~I~~R~~D~~PR~~K~~-G~~V~~R~~V~~WLGT~~F~~NT~~A~~EE~~A~~AMAYD~~V~~A~~A~~K~~Q~~I~~R~~G~~D~~K~~A~~LNFP 135

SEQ ID NO:82 (G25) Conserved domain = residues 47-114
MCGGAIISDFIWSKSESEPSQLGSVSSRKPKVSVSEERDGKRERKNLYRGIRQRPWGKWAAEIRDPSKGVRVWLGT
TFKTADEAARAYDVAAIKIRGRKAKLNFPNTQVEEEADTKPGGNQNELISENQVESLSEDLMAL
DQSATDIGNLWSYQDSN

SEQ ID NO:82 (G25) (Amino Acid Sequence) (gf=1)

Length = 171

Score = 90.9 bits (224), Expect = 8e-21

Identities = 42/58 (72%), Positives = 51/58 (87%), Gaps = 1/58 (1%)

Query: 4 YRGVRQRPWGKFAAEIRDPAKNGARVWLGTFETAEDAALAYDRAAFRMRGSRALLNFP 61
YRG+RQRPWGK+AAEIRDPAK G RVWLGTF+TA++AA AYD AA ++RG +A LNFP

Sbjct: 50 YRGIRQRPWGKFAAEIRDPSK-GVRVWLGTFKTADEAARAYDVAAIKIRGRKAKLNFP 106

SEQ ID NO:34 (G1006) Conserved domain = residues 114-182
MYGQCNIESDYALLESITRHLLGGGGENELRLNESTPSSCFTESWGGLPLKENDSEDMVYGLLKDAFHFDTSSSDL
SCLDFPAVKVEPTENFTAMEEKPKKAIPVTETAVKAKHYRGVRQRPWGKFAAEIRDPAKNGARVWLGTFETAEDA
LAYDIAAFRMRGSRALLNFPLRVNSGEPDPRITSKRSSSSSSSSSTSSSENGKLKRRKAENLTSEVVQVKCEV
GDETRVDELLVS

SEQ ID NO:34 (G1006) (Amino Acid Sequence) (gf=1)

Length = 243

Score = 140 bits (353), Expect = 9e-36

Identities = 67/68 (98%), Positives = 67/68 (98%)

Query: 2 KHYRGVRQRPWGKFAAEIRDPAKNGARVWLGTFETAEDAALAYDRAAFRMRGSRALLNFP 61
KHYRGVRQRPWGKFAAEIRDPAKNGARVWLGTFETAEDAALAYD AAFRMRGSRALLNFP

Sbjct: 115 KHYRGVRQRPWGKFAAEIRDPAKNGARVWLGTFETAEDAALAYDIAAFRMRGSRALLNFP 174

Query: 62 LRVNSGEP 69


LRVNSGEP

Sbjct: 175 LRVNSGEP 182

APPENDIX F

卷二

Summary of BLAST against PREFGENE dataset minimum match cutoff 50%



Mendel BLAST query on *Arabidopsis* sequences

full BLAST options and parameters, refer to the NCBI BLAST Documentation. Links to GenBank, MMBL, PIR, and SwissProt are shown in **bold** type; links to locations within this document are in normal

ASTB 213 [Apr 1 2001]

References:

- Altschul, Stephen F., Gish, Warren, Miller, Webb, Myers, (1990). Basic local alignment search tool. *J. Mol. Biol.* **214**: 403-410.
- Gish, Warren, and David I. States (1993). Identification of similarity search. *Nature Genetics* **3**:266-72. [PubMed]
- Gish, Warren (1994) unpublished. BLAST2 Documentation

Query Sequence: G28 (Length: 268)

Sequence	Value	(bits)
G228 (Amino Acid Sequence) ($gf=1$)	535	e-154
G11006 (Amino Acid Sequence) ($gf=1$)		2e-73
G22 (Amino Acid Sequence) ($gf=1$)		2e-41
G11004 (Amino Acid Sequence) ($gf=1$)		1e-41
G11005 (Amino Acid Sequence) ($gf=1$)		1e-31
G229 (Amino Acid Sequence) ($gf=1$)		1e-28
G11266 (Amino Acid Sequence) ($gf=1$)		1e-27
G46 (Amino Acid Sequence) ($gf=1$)		1e-26
G2299 (Amino Acid Sequence) ($gf=1$)		1e-15
G2138 (Amino Acid Sequence) ($gf=1$)		7e-16
G38 (Amino Acid Sequence) ($gf=1$)		7e-16
G975 (Amino Acid Sequence) ($gf=1$)		7e-16
G180 (Amino Acid Sequence) ($gf=1$)		7e-15
G442 (Amino Acid Sequence) ($gf=1$)		7e-15
G1754 (Amino Acid Sequence) ($gf=1$)		7e-15
G1007 (Amino Acid Sequence) ($gf=1$)		7e-15
G2299 (Amino Acid Sequence) ($gf=1$)		2e-15

Query: 88 NDAPHQWPEPSSSSDEDRSPSPVKIETPESPAFDSPVPKETKSPVSKAFTVAAVTAKGKHH 147
 Sbjct: 80 ND-F P + R + P + KI P + + PV V A + H
 Sbjct: 80 NDPSQFQNPSQFVQSNR - - PELKI APPRPTKPTWQFQATGPNKPKEPLPVY - VAAEBCRH 136

Query: 148 YRGRVORPQSPKFAEIRDPAKNGKARVWLTGFTETEDALDAVDRAPMRGSRALINPFL 207
 Sbjct: 137 YRCVRMRPQSPKFAEIRDPTTRGTRVWLTGFTETIAEARYDKEAFLRGSKAALINPFL 196

Query: 208 VNSGBDPDPRIKSKRSRSPSSNENG 232
 Sbjct: 197 VDKWNP--RAEGRGLYNKRKG 218

Query: 66 -QDPLIKTSRSRSKSYRCVRPQGKFAEIRDSTRNGIRVWLTGFTESAREALAYDQ 124
 Sbjct: 125 AAPFMRGSSA1NPF 138

>G1266 (Amino Acid Sequence) (gf=1)
 Length = 218

Score = 113 bits (283), Expect = 7e-27
 Identities = 61/134 (45%), Positives = 79/134 (58%), Gaps = 31/134 (23%)

Query: 71 LPKENDSMDLIVYGLNDFHGWMWPESSSSDEDRSPSPVKIETPESPAFDSPVPKH 130
 Sbjct: 36 LPENDSMDLIVYGLNDFHGWMWPESSSSDEDRSPSPVKIETPESPAFDSPVPKH 130

Query: 131 EKTPSPVSAVTAAKGKHYRORPQKPKAETRDPAKNGKARVWLTGFTETEDALAYD 190
 Sbjct: 131 EKTPSPVSAVTAAKGKHYRORPQKPKAETRDPAKNGKARVWLTGFTETEDALAYD 190

Query: 191 AAPMRGSRALINP 204
 Sbjct: 125 AAPFMRGSSA1NPF 138

>G46 (Amino Acid Sequence) (gf=1)
 Length = 207

Score = 110 bits (276), Expect = 4e-26
 Identities = 73/154 (47%), Positives = 89/154 (57%), Gaps = 16/154 (10%)

Query: 71 LPKENDSMDLIVYGLNDFHGWMWPESSSSDEDRSPSPVKIETPESPAFDSPVPKH 130
 Sbjct: 48 VPKQFEDSPVLDPSDFVNEFLQVGESSSSSPLNNS--SSTVETDOSV----- 95

Query: 131 EKTPSPVSAVTAAKGKHYRORPQKPKAETRDPAKNGKARVWLTGFTETEDALAYD 190
 Sbjct: 96 KKAEREEVDA - HYRGRVORPQKPKAETRDPAKNGKARVWLTGFTETEDALAYD 190

Query: 191 AAPMRGSRALINPFLVRSGB - PDPVRIKRS 223
 Sbjct: 153 AAPKLQRGRCAVNLNPLDAGKYEAPANSGRKRS 186

>G43 (Amino Acid Sequence) (gf=1)
 Length = 201

Score = 110 bits (276), Expect = 4e-26
 Identities = 62/128 (48%), Positives = 82/128 (63%), Gaps = 3/128 (2%)

Query: 96 EPSSSDDDRSRSPVKIETPESPAFDSPVPKETKSPVSAVTAAKGKHYRORP 155
 Sbjct: 56 EPSSDPSYDPSVQELLNEAESSSSSSTTSPVEVTSRKTKRFBETHYRGVRP 114

Query: 156 WKEKFAEIRDPAKNGKARVWLTGFTETEDALDAVDRAPMRGSRALINPFL 214
 Sbjct: 115 WOKPAEIRDPAKNGKARVWLTGFTETEDALDAVDRAPMRGSRALINPFL 214

```

Query: 215 PVRKSKR 222
  PV KR
Sbjct: 173 PVNSCRKR 180

>G1791 (Amino Acid Sequence) (gf=1)
Length = 139
Score = 110 bits (274), Expect = 8e-26
Identities = 58/105 (55%), Positives = 66/105 (62%), Gaps = 10/105 (9%)

Query: 148 YRGVRPQPGKPKAAEIRDPAKNGKARVNLGTPTETADAALAYDRAAFMGRGSRALINPFLR 207
  YRGVRPQPGKPKAAEIRDPAKNGKARVNLGTPTETADAALAYDRAAFMGRGSRALINPFLR MRC RA LNPF
Sbjct: 14 YRGVRPQPGKPKAAEIRDPAKNGKARVNLGTPTETADAALAYDRAAFMGRGSRALINPFLR 73

Query: 208 VNSGEPDPVRIKSKRSSFSNENGAPKKRRTVAGGCMGDKGLTV 252
  + P + S+EN GGG D G V
Sbjct: 74 YQMMKQDP-----NSHENAVASSSSSYRGCGGDCREV 108

>G1792 (Amino Acid Sequence) (gf=1)
Length = 139
Score = 107 bits (268), Expect = 4e-25
Identities = 55/92 (59%), Positives = 69/92 (74%), Gaps = 5/92 (5%)

Query: 144 KGKHYRGCVRQPRNGKPKAAEIRDPAKNGKARVNLGTPTETADAALAYDRAAFMGRGSRALIN 203
  K +RCVR+RPNGKPKAAEIRDPAKNGKARVNLGTPTETADAALAYDRAAFMGRGSRALIN +RCVR+ +RGA
Sbjct: 16 KQARPRFREVRRPQGKPKAAEIRDPAKNGKARVNLGTPTETADAALAYDRAAFMGRGSRALIN 75

Query: 204 PPLRVNSGEP -DPVRIKSKRSSFSNENGKA 233
  PP N P D ++ +S SSS + +G+
Sbjct: 76 PP--NEYPRMDYSLRPYASSSSSSSS 104

>G1841 (Amino Acid Sequence) (gf=1)
Length = 229
Score = 107 bits (267), Expect = 5e-25
Identities = 66/139 (47%), Positives = 80/139 (57%), Gaps = 4/139 (2%)

Query: 94 CWPSSSSSBEDRSSSPPSVSKIETPESPAVDSV -PVVKKEKTSVPSUSAATVAKGKHYRGV 151
  G SSS+ R P SFA VDS P++ S + S K + YRGV
Sbjct: 31 GASSSSAGHKGQWLGIDSAPISVPPQDSINPNT -BMSMCAFPEAKERKRRGK 89

Query: 152 ROPPGKPKAAEIRDPAKNGKARVNLGTPTETADAALAYDRAAFMGRGSRALINPFLR 211
  ROPPGKPKAAEIRDPAKNGKARVNLGTPTETADAALAYDRAAFMGRGSRALINPFLR MRC RA LNPF V
Sbjct: 90 ROPPGKPKAAEIRDPAKNGKARVNLGTPTETADAALAYDRAAFMGRGSRALINPFLR 148

Query: 212 EPPDPVRIKSKRSSFSNNE 230
  P P + +S + +E
Sbjct: 149 PPPPLRSPADTVNKA 167

>G2512 (Amino Acid Sequence) (gf=1)
Length = 244
Score = 107 bits (266), Expect = 6e-25
Identities = 64/143 (44%), Positives = 82/143 (56%), Gaps = 16/143 (11%)

Query: 95 WEPSSSSSBEDRSSSPPSVSKIETPESPAVDSVVKKEKTSVPSUSAATVAKGKHYRGV 153
  WBS D S + +D P + +S +K+E AA + K YRGV+
Sbjct: 30 WEPSSSSSBEDRSSSPPSVSKIETPESPAVDSVVKKEKTSVPSUSAATVAKGKHYRGV 153

```


Query: 133 TSPVSAVTAAGKHYGRVORPGKPAEIRDPAKNGARYWLGTPETAEDALAYDRAA 192
 Sbjct: 46 TKEESSNISLERPKKVKRGRVORPGKPAEIRDPK-AAEIRDP K RVWLGTPETAEDALAYDRAA 104

Query: 193 PRMGSRALNPLRVNS 210
 Sbjct: 105 LRPGSKAKLKNPENVT 122

>G45 (Amino Acid Sequence) (gf=1)
 Length = 349

Score = 96.3 bits (238), Expect = 1e-21
 Identities = 56/133 (42%), Positives = 73/133 (54%), Gaps = 27/133 (20%)

Query: 107 SPPSPVKETPEAVDPSVVKETPSVSAVTAAGKHYGRVORPGKPAEIRDP 166
 Sbjct: 124 ASPPNKTNHDPLNPTIDSCSLSR-----+VSGKTRKVRKVRKPGKPAEIRDS 174

Query: 167 AKNGARYWLGTPETAEDALAYDRAAPMRS-RALLNPLRV-----+K + YGYTR+PGKPAEIRDP 208
 Sbjct: 175 TRNGVRWLGTPQTAEEAAYDKAVERGKQTAHKTNPOLETEVKAEMDCPNYRMN 234

Query: 209 NSGPDPVRKSK 221
 Sbjct: 235 NSNTSDPLRSRK 247

>G19 (Amino Acid Sequence) (gf=1)
 Length = 248

Score = 96.3 bits (238), Expect = 1e-21
 Identities = 60/141 (42%), Positives = 79/141 (55%), Gaps = 6/141 (4%)

Query: 95 WPESSSSDDESSSPVKETPSVSAVTAAGKHYGRVOR 154
 Sbjct: 28 WSBLDASADDPMGFSYTSKLHPTNQVNKVKEAVKEQAT--EPGKRRKAKVYRGIRKR 85

Query: 155 PWGKPAEIRDPDPAKNGARYWLGTPETAEDALAYDRAAPMRS-PVNLVNSGEBD 214
 Sbjct: 86 PWGKMAEIRDPRE-GVYRMLGTTNTABAMAYDVAQKIRGDRAKLNP--DLHIPP 141

Query: 215 PVRKSKRSFSSNENGAPK 235
 Sbjct: 142 PPNTPPPSSPQRSTDQPPAK 162

>G14 (Amino Acid Sequence) (gf=1)
 Length = 358

Score = 95.5 bits (236), Expect = 2e-21
 Identities = 62/127 (48%), Positives = 77/127 (59%), Gaps = 13/127 (10%)

Query: 91 PHGGWBPSSSSDED----RSPSPVKETPE---SPAVDPSVVKETPSVSAV 140
 Sbjct: 56 PG + SS D-D P G + SS D-D FQGKDDSDIDCDDPFDVGDVPAVSKAEGSVGKVTGDDAK 115

Query: 141 TAAGKGR-HYRGYRQRPWPGKPAEIRDPAKNGARYWLGTPETAEDALAYDRAAPMRS 198
 Sbjct: 116 SADRKRKQYRGRQRPWPGKWAEEIRDP + GAR WLGTP-TAA AA YD AA R+RGS 174

Query: 199 RALLNPP 205
 Sbjct: 175 KARVNPP 181

>G1008 (Amino Acid Sequence) (gf=1)
 Length = 294

Score = 94.4 bits (233), Expect = 4e-21
 Identities = 55/117 (47%), Positives = 66/117 (56%), Gaps = 9/117 (7%)

Query: 96 EPSSSSDDESSSPVKETPE---SPAVDPSVVKETPSVSAV 147
 Sbjct: 39 DSSDENDKNSVAPVRYRYDEIFPCDDDPKPKAKKSPANAAENGDLVLSVVK 98

Query: 148 YGYTROPPWPGKPAEIRDPDPAKNGARYWLGTPETAEDALAYDRAAPMRSRALNPP 204
 Sbjct: 99 YRGYRQPPWPGKPAEIRDPSSR-TRNLQGTPATAEEAIGYDRAIRKHNQATNF 154

>G1421 (Amino Acid Sequence) (gf=1)
 Length = 287

Score = 94.0 bits (232), Expect = 6e-21
 Identities = 56/121 (46%), Positives = 76/121 (62%), Gaps = 16/121 (13%)

Query: 99 SSSDDESSSPVKETPSVSAV 144
 Sbjct: 25 SSSDDEBVDODDASTKRRVYKVKYEVVLDVSVDSDKEKPMKGRKRVVTVVVVTAT 84

Query: 145 GHYRGYRQRPWPGKPAEIRDPAKNGARYWLGTPETAEDALAYDRAAPMRSRALNPP 204
 Sbjct: 85 K+RGRQRPWPGKWAEEIRDPSSR - VRWLGTP-TAA AA YD AA +RGS A LNP 142

Query: 205 P 205
 Sbjct: 143 P 143

>G1794 (Amino Acid Sequence) (gf=1)
 Length = 391

Score = 93.6 bits (231), Expect = 7e-21
 Identities = 51/89 (57%), Positives = 59/89 (65%), Gaps = 6/89 (6%)

Query: 146 KHYRGYRQRPWPGKPAEIRDPAKNGARYWLGTPETAEDALAYDRAAPMRSRALNPP 205
 Sbjct: 183 RYFGRQRPWPGKWAEEIRDPK-AARWLGTPDNEASARAYDEALPRGKAKLNP 241

Query: 206 -----LRVNSGEPDPRVSKRSFSSN 229
 Sbjct: 242 ENVKLVRPASTEAQPVHQTAAQRQPTQSN 270

>G440 (Amino Acid Sequence) (gf=1)
 Length = 354

Score = 92.8 bits (229), Expect = 1e-20
 Identities = 66/177 (37%), Positives = 88/177 (49%), Gaps = 31/177 (17%)

Query: 56 SFSKLYQPFBSWMDLPKENDSEDML-----VIGELNDAPHGQWPBSS-----SSSD 103
 Sbjct: 35 SLKRVISCYTDPPDATSSSDEBPLPDRRVKRFVNE-TV--EPSCLNNVVTGVSMDK 91

Query: 104 EDRSSSPVVKLBTPPSPAVDSVPTKETPSVSAVTAAGKHYGRVORLPNGKPAABI 163
 Sbjct: 92 RKRLLSSSDEQPSA-----+P + + + K +RCVRQRPKCK-AAEI 140

Query: 164 RDPAKNGARYWLGTPETAEDALAYDRAAPMRSRALNPP-----RVNSGEPDPV 216

RDP + R+MLGTFETAA+AA+ YD AA R+RG AL NP + EP-PV
 Sbjct: 141 RDPDQR RRIWLGTFETAA+AA+YDAA R+RG AL NP + EP-PV 196

>G31 (Amino-Acid Sequence) (gf=1)
 Length = 200

Score = 92.0 bits (227), Expect = 4e-20
 Identities = 46/82 (56%), Positives = 55/82 (66%), Gaps = 1/82 (1%)

Query: 125 SVPVKKETSPVSAVTAAGKHYGRQVRPQKGKFAAEIRDPAKNGARVWLGTFTTADA 184
 S+ V + T K H+RGR+RHWG+AAEIRDPK K RWLGT+TAE+KALAYD+AA+ 142
 Sbjct: 10 SIAVSGCGKGTMTMTRIKVHPRGVKRWGGRYAAEIRDGRK -TRWMLGTDTAAE 68

Query: 185 ALAYDRAAFMRGSRALLNPL 206
 Sbjct: 1 A YD AA RGS+A NPL 184

Sbjct: 69 ARAYDTAAREFRGSKAKTNPL 90

>G25 (Amino Acid Sequence) (gf=1)

Length = 171

Score = 92.0 bits (227), Expect = 2e-20

Identities = 51/94 (54%), Positives = 64/94 (67%), Gaps = 11/94 (11%)

Query: 117 PSEAAVDSVPVKEXTSPVSAVTAAGKHYGRQVRPQKGKFAAEIRDPAKNGA 171
 P -+V S +K PVS + K RWLGT+TAE+KALAYD+AA+ 142
 Sbjct: 19 PSQGSVTS ---+RKGKGPVSVS - EBDGKREKRNLRGKIQRPGKWAEEIRDFSK-GV 72
 Query: 172 RWLGTFTETAAEALAYDRAAFMRGSRALLNPL 205
 Sbjct: 72 RWLGT+TAE+AA AYD AA R+RG +A NPL 171
 Sbjct: 73 RWLGTFTKTADEAAEALAYDRAAFMRGSRALLNPL 106

>G1763 (Amino Acid Sequence) (gf=1)

Length = 314

Score = 91.3 bits (225), Expect = 4e-20

Identities = 53/113 (46%), Positives = 68/113 (59%), Gaps = 11/113 (9%)

Query: 137 SAAVTAAGKHYGRQVRPQKGKFAAEIRDPAKNGARVWLGTFTETAAEALAYDRAAFMR 196
 S+ + K YGVGR WKG+ AETR P +N R+MLGT+TAE+KALAYD+AA+ 190

Sbjct: 132 SSGSVSKPAPLYGRQVRHKGKVAEIRLP -RNTRMLGTDTAAEALAYDRAAFPLR 190
 Query: 197 GSRAALNPP-LRVNSG------ PDPYRKSKRQSSPSSNENGAPKERT 239
 Sbjct: 191 GDSARLNPPALRYQTGSSSPDSVGYGPQIAQAAVDAKLEAIIALEPKNQPKTERT 243

>G1384 (Amino Acid Sequence) (gf=1)

Length = 314

Score = 91.3 bits (225), Expect = 4e-20

Identities = 53/113 (46%), Positives = 68/113 (59%), Gaps = 11/113 (9%)

Query: 137 SAAVTAAGKHYGRQVRPQKGKFAAEIRDPAKNGARVWLGTFTETAAEALAYDRAAFMR 196
 S+ + K YGVGR WKG+ AETR P +N R+MLGT+TAE+KALAYD+AA+ 190

Sbjct: 132 SSGSVSKPAPLYGRQVRHKGKVAEIRLP -RNTRMLGTDTAAEALAYDRAAFPLR 190
 Query: 197 GSRAALNPP-LRVNSG------ PDPYRKSKRQSSPSSNENGAPKERT 239
 Sbjct: 191 GDSARLNPPALRYQTGSSSPDSVGYGPQIAQAAVDAKLEAIIALEPKNQPKTERT 243

>G974 (Amino Acid Sequence) (gf=1)

Length = 314

Score = 91.3 bits (225), Expect = 4e-20

Identities = 53/113 (46%), Positives = 68/113 (59%), Gaps = 11/113 (9%)

Query: 137 SAAVTAAGKHYGRQVRPQKGKFAAEIRDPAKNGARVWLGTFTETAAEALAYDRAAFMR 196
 S+ + K YGVGR WKG+ AETR P +N R+MLGT+TAE+KALAYD+AA+ 190

Sbjct: 132 SSGSVSKPAPLYGRQVRHKGKVAEIRLP -RNTRMLGTDTAAEALAYDRAAFPLR 190
 Query: 197 GSRAALNPP-LRVNSG------ PDPYRKSKRQSSPSSNENGAPKERT 239
 Sbjct: 191 GDSARLNPPALRYQTGSSSPDSVGYGPQIAQAAVDAKLEAIIALEPKNQPKTERT 243

>G439 (Amino Acid Sequence) (gf=1)

Length = 279

Length = 261

Score = 91.3 bits (225), Expect = 4e-20
 Identities = 61/172 (35%), Positives = 92/172 (53%), Gaps = 16/172 (9%)

Query: 97 PSSSSBDRSSPFSVKIETPESAA-----VDSVPVKKEKTPSPVSAAVTAAGKHY 146
 Sbjct: 29 PPIKSPNDSSAP-AFSIUPATISVGSDLHSFSHSPKPVTSKAKT---KLY 63

Score = 92.0 bits (227), Expect = 2e-20
 Identities = 46/82 (56%), Positives = 55/82 (66%), Gaps = 1/82 (1%)

Query: 125 SVPVKKETSPVSAVTAAGKHYGRQVRPQKGKFAAEIRDPAKNGARVWLGTFTADA 184
 S+ V + T K H+RGR+RHWG+AAEIRDPK K RWLGT+TAE+KALAYD+AA+ 142
 Sbjct: 10 SIAVSGCGKGTMTMTRIKVHPRGVKRWGGRYAAEIRDGRK -TRWMLGTDTAAE 68

Query: 185 ALAYDRAAFMRGSRALLNPL 206
 Sbjct: 1 A YD AA RGS+A NPL 184

Sbjct: 69 ARAYDTAAREFRGSKAKTNPL 90

>G33 (Amino Acid Sequence) (gf=1)

Length = 245

Score = 90.9 bits (224), Expect = 5e-20
 Identities = 50/93 (53%), Positives = 58/93 (61%), Gaps = 5/93 (5%)

Query: 118 EFAAVIDSPVVKREKTPSPVSAAVT---AAAGKHYGRVQRPWKGPKAABIRDPAKNGARY 173
 Sbjct: 19 E V VPK K + AV YRGV+RHWG+AAEIRDPK K RV EKSKVESDKGWKKKVNATKALAVNDGGEKSKEVTRPGRYAAEIRDPKK-KRV 77

Query: 174 WLGTFTETAAEALAYDRAAFMRGSRALLNPL 206
 Sbjct: 78 WLGSNTNGEAAAYDSAAIRPFSKATTNPL 110

>G1932 (Amino Acid Sequence) (gf=1)

Length = 189

Score = 90.5 bits (223), Expect = 6e-20
 Identities = 44/68 (64%), Positives = 53/68 (77%), Gaps = 1/68 (1%)

Query: 138 AAATTAAGKHYGRQVRPQKGKFAAEIRDPAKNGARVWLGTFTETAAEALAYDRAAFMR 197
 Sbjct: 2 A+ T A+ HYRGV+RHWG+AAEIRDPK K RVWLGTP-T E+AAEIRDAA +RG
 Query: 198 SRAALNPP 205
 Sbjct: 61 IKAKTNPP 68

>G1005 (Amino Acid Sequence) (gf=1)

Length = 225

Score = 90.5 bits (223), Expect = 6e-20
 Identities = 47/88 (53%), Positives = 61/88 (68%), Gaps = 1/88 (1%)

Query: 136 VSAAVTAAGKHYGRQVRPQKGKFAAEIRDPAKNGARTWLGTFTETAAEALAYDRAAFMR 195
 Sbjct: 16 V+A + K +RGTP+RHWG+AAEIRDPK K ARWLGTP+AB+AA AYDAA +
 Query: 196 RGSRALLNPLRVNSG------ PDPYRKSKRQSSPSSNENGAPKERT 223
 Sbjct: 75 RGPKAKTNPPIDSSPPNLRPQIRN 102

>G439 (Amino Acid Sequence) (gf=1)

Length = 279

8/27/02 11:30 AM

13 of 728

Score = 89.4 bits (220), Expect = 1e-19
 Identities = 56/122 (45%), Positives = 70/122 (56%), Gaps = 7/122 (5%)
 Query: 133 TSPVSAAVTAAGKHYRQRPKPAEIRDPAKNGARVWLGTPTETAADALAYDRAA 192
 Sbjct: 98 TSMKKIDVATKPKVLYKGVRQNGKVAEIRLP-KNTRMLGTPTETAADALAYDQAA 156
 Score: 88.2 bits (217), Expect = 3e-19
 Identities = 50/103 (48%), Positives = 65/103 (62%), Gaps = 13/103 (12%)
 Query: 103 DEPRSSPPSKVIEPTPESPAVDSVPUVKEKTPSPUSAATTAAKGKHYRQVRQRPCKPNAE 246
 Sbjct: 157 HKTRGDNALENPDPDVOQHYKQOLSPSINKKIESIGNSDPLPQLEKONKTEVLSGP 216
 Score: 87.4 bits (215), Expect = 5e-19
 Identities = 47/82 (57%), Positives = 57/82 (69%), Gaps = 2/82 (2%)
 Query: 148 YRGVRQRPNGKPAEIRDPAKNGARVWLGTPTETAADALAYDRAA 207
 Sbjct: 71 YRGVRQRPNGKWAERLP-KNTRMLGTPTETAADALYDQAA 129
 Score: 86.3 bits (214), Expect = 7e-19
 Identities = 41/60 (68%), Positives = 50/60 (83%), Gaps = 1/60 (1%)
 Query: 146 KHYGVYRQRPNGKPAEIRDPAKNGARVWLGTPTETAADALAYDRAA 205
 Sbjct: 162 K YRGVRQRPNGKWAERLP-AEIR P ++ AT+WLGT+TAB+AAAYD AR+*+RG A LNFP 199
 Score: 87.0 bits (214), Expect = 7e-19
 Identities = 41/60 (68%), Positives = 50/60 (83%), Gaps = 1/60 (1%)
 Query: 141 KLYGVYRQRPNGKWAERLP-RSARLWLGTDREAAHYDRAQFKLRLRHSATLNFP 199
 Sbjct: 130 1HEDMPLPSSVDTKLQACKS 151

>G1845 (Amino Acid Sequence) (gf=1)
 Length = 292

Score: 86.3 bits (214), Expect = 7e-19
 Identities = 54/111 (49%), Positives = 66/111 (58%), Gaps = 9/111 (8%)
 Query: 130 KBTSPVPSAVTAAGKHYRQRPNGKPAEIRDPAKNGARVWLGTPTETAADALAYD 189
 Sbjct: 171 KSKTRKVQQTTPK--LYGVRQRHNGKWAERLP-RNTRMLGTPTETAQAMAYD 227
 Score: 86.3 bits (212), Expect = 1e-18
 Identities = 54/111 (49%), Positives = 66/111 (58%), Gaps = 9/111 (8%)
 Query: 190 RAAFNRGSPSALLNPLRVSNSGPDPYR-----IKSRSSPSNNENGAP 234
 Sbjct: 155 PVA+ + K YRGVR+RPG+ +A LNFP + +R + +SK SSS + +P 278
 Score: 86.3 bits (212), Expect = 1e-18
 Identities = 53/108 (49%), Positives = 64/108 (58%), Gaps = 10/108 (9%)
 Query: 193 RMGRGSPSALLNPLRVSNSGPDPYR-----TRWLGTFDAAQPARAYDAA 74
 Sbjct: 228 TAAYILRGSPAHLNPDQLHQKLSGSLRCMIALESKIQISSSQVNSP 228

>G1020 (Amino Acid Sequence) (gf=1)
 Length = 185

Score: 86.3 bits (212), Expect = 1e-18
 Identities = 45/78 (57%), Positives = 53/78 (67%), Gaps = 1/78 (1%)
 Query: 133 TSPVSAAVTAAGKHYRQRPNGKPAEIRDPAKNGARVWLGTPTETAADALAYDRAA 192
 Sbjct: 16 TNPTHHESNRAKEIRGVKRPGRVAAEIRDPKV-TRWLGTFDAAQPARAYDAA 74

>G6 (Amino Acid Sequence) (gf=1)
 Length = 222

Score: 86.3 bits (212), Expect = 1e-18
 Identities = 42/63 (66%), Positives = 49/63 (77%), Gaps = 1/63 (1%)
 Query: 143 AKGKHYGVYRQRPNGKPAEIRDPAKNGARVWLGTPTETAADALAYDRAA 202
 Sbjct: 92 RYDRAAVLYGSGRAQINLTPSSPSVSSSS-SSVSAASSPSTSSSTOLRPLPPEAA 150

>G625 (Amino Acid Sequence) (gf=1)
 Length = 328

Score: 88.2 bits (217), Expect = 3e-19
 Identities = 63/130 (48%), Positives = 71/130 (54%), Gaps = 16/130 (12%)
 Query: 134 SPVSAAVTAAGKGR-----HYGVYRQRPNGKPAEIRDPAKNGARVWLGTPTETAADAA 185
 Sbjct: 33 SSSSSQRCRKGKGGPDNSKPRVGRQWSKGWVIREPRKR-TRWLGTFDAA 91

>G186 (Amino Acid Sequence) (gf=1)
 Length = 241

Score: 86.3 bits (212), Expect = 1e-18
 Identities = 42/63 (66%), Positives = 49/63 (77%), Gaps = 1/63 (1%)
 Query: 186 LAYDRAAVLYGSGRAQINLTPSSPSVSSSS-SSVSAASSPSTSSSTOLRPLPPEAA 150
 Sbjct: 92 RYDRAAVLYGSGRAQINLTPSSPSVSSSS-SSVSAASSPSTSSSTOLRPLPPEAA 150

>G28 (Amino Acid Sequence) (gf=1)
 Length = 268

Score: 86.3 bits (212), Expect = 1e-18
 Identities = 42/63 (66%), Positives = 49/63 (77%), Gaps = 1/63 (1%)
 Query: 242 A-GGMDIG 249
 Sbjct: 151 ATGGGAGTC 160

Sbjct: 20 AKEIRYRGVRKRPNGRYAAIRDPGKK-TRWLGTFDTAEEAARYDFTARDPFRGAKAKT 78
 Query: 203 NPP 205
 Sbjct: 79 NPP 81

>G1796 (Amino Acid Sequence) (gf=1)
 Length = 328
 Score = 85.9 bits (211), Expect = 2e-18
 Identities = 52/128 (40%), Positives = 66/128 (50%), Gaps = 9/128 (7%)
 Query: 110 PSVKTIEPESFAAVIDSVTPVKEKTPSPVSAATAKGKHYRVRGPNGKFAAEIRDPAVN 169
 Sbjct: 19 P K T + + V PLTKPFTPEFTASPVSPNPKSSKDTVTIAGAGSSTRYGVRRRPWRYAAIRDPMK 78
 Query: 170 GARWLGTFETASDAALAYDRAAFRMRGSRALINPLRVNSGEPDPVRIKSKRSSPSSN 229
 Sbjct: 79 R R HICP+TAE AA AID AA P G+ + A, NF P A P RS SN
 Query: 230 ENGAPKRR 237
 Sbjct: 130 KRSPPSAR 137

>G5 (Amino Acid Sequence) (gf=1)
 Length = 334
 Score = 85.9 bits (211), Expect = 2e-18
 Identities = 42/68 (61%), Positives = 53/68 (77%), Gaps = 1/68 (1%)
 Query: 138 AAVTAAGKHYRVRGPNGKFAAEIRDPAKNGARWLGTFETADALAYDRAAFRMRG 197
 Sbjct: 142 SGVPSKPTKLYRGVRQHNSKWKVABILP-RNTRNLIGTPDTEAALAYDRAKYKURG 200
 Query: 198 SRALNPP 205
 Sbjct: 201 DFARLNPP 208

>G2113 (Amino Acid Sequence) (gf=1)
 Length = 166
 Score = 85.1 bits (209), Expect = 3e-18
 Identities = 39/61 (63%), Positives = 48/61 (77%), Gaps = 1/61 (1%)
 Query: 145 GKHRYGRVRGPNGKFAAEIRDPAKNGARWLGTFETADALAYDRAAFRMRGSRALINP 204
 Sbjct: 17 GYVRYGRKRPNGRYAAEIRDPPKK-SRVNLGTPDPEAARYDRAEPRGAKATNF 75

>G2571 (Amino Acid Sequence) (gf=1)
 Length = 335
 Score = 84.7 bits (208), Expect = 3e-18
 Identities = 43/70 (61%), Positives = 52/70 (73%), Gaps = 1/70 (1%)
 Query: 136 VSAAVTAAGKHYRVRGPNGKFAAEIRDPAKNGARWLGTFETADALAYDRAAFR 195
 Sbjct: 124 LAGRVTKKKLYRGVRQHNGKWAIRLP-QNRMWLGTFDTAEEAAYDRAAYKL 182

Query: 196 RGSRALNPP 205
 Sbjct: RG A LNPP
 Sbjct: 183 RGYARLNPP 192

>G36 (Amino Acid Sequence) (gf=1)
 Length = 272
 Score = 84.3 bits (207), Expect = 4e-18
 Identities = 41/60 (68%), Positives = 49/60 (81%), Gaps = 1/60 (1%)
 Query: 146 KHTRGYQRPNGKFAAEIRDPAKNGARWLGTFETADALAYDRAAFRMRGSRALINP 205
 Sbjct: 91 KLYRGVRQHNGKWAIRLP-KNTRLWLGTFDTAEEAAMAYDLAATYKLREFAEIRLNPP 149

>G32 (Amino Acid Sequence) (gf=1)
 Length = 211
 Score = 82.4 bits (202), Expect = 2e-17
 Identities = 40/60 (66%), Positives = 47/60 (77%), Gaps = 1/60 (1%)
 Query: 145 GKHRYGRVRGPNGKFAAEIRDPAKNGARWLGTFETADALAYDRAAFRMRGSRALINP 204
 Sbjct: 9 G + GVR+RPWG+AAIRD P R WLGTF+TAE+ALAYDRAA MSG+RA NF
 Sbjct: 17 GTRPLGVRRPWRGKRYAAEIRDPTTK-BRHWLGTFDTAEEAALAYDRAARSMSGTARTNF 75

>G35 (Amino Acid Sequence) (gf=1)
 Length = 159
 Score = 82.0 bits (201), Expect = 2e-17
 Identities = 57/127 (44%), Positives = 68/127 (52%), Gaps = 16/127 (12%)
 Query: 98 SSSSSDEDSSPPSVKLTBTPESPAVDSVPPVKEKTS-----SPVSAAVTAAGKHYR 149
 Sbjct: 17 SSSS DE S + + S P + KT S + + A T A K + R
 Sbjct: 17 SSSSDEDSSPPSSRRGKLVKEIVIDHSDDPPEVGTRPKRIPASLLAARNNTANKKKFR 76

Query: 150 GVRQRPNGKFAAEIRDPAKNGA - RVWLGTFETADALAYDRAAFRMRGSRALINP 207
 Sbjct: 77 GVRQRPNGKWAALI RGRVGRPBRPBLPEAARYDRAAFRMRGSRALINP 207
 Query: 208 VNSGEPD 214
 Sbjct: 134 ---GRPD 137

>G1415 (Amino Acid Sequence) (gf=1)
 Length = 206
 Score = 81.3 bits (199), Expect = 4e-17
 Identities = 49/129 (37%), Positives = 72/129 (54%), Gaps = 14/129 (10%)
 Query: 129 KKEKTSFVSAAVTAAGKSH-----YRGYRQRPWGKPAEIRDPAKNGARWLGTFET 180
 Sbjct: 15 KK+T S + +GK Y+GYRQ R WCK+ A EIR P + GAF+WLGTF+T
 Sbjct: 15 KQRTVQASSRKGCMRGGPDNACTYKGTQRWTGKWKVABIREPNR-GARWLGTFDT 73

Query: 181 AEDALAYDAAFRMRGSRALINP 235
 Sbjct: + +AALAYD AA ++ G A LN P + S P + SS+++ +P
 Sbjct: 74 SREAAALYDAAARKLYGPEAHNLPESLRSTPKTASSPQTSSNTGKSSSDSBSPC 133

Query: 236 KRTVAGG 244
 Sbjct: 134 SSNEMESSCG 142

>G23 (Amino Acid Sequence) (gf=1)
Length = 236

Score = 80.1 bits (196), Expect = 8e-17
Identities = 44/109 (40%), Positives = 68/109 (62%), Gaps = 1/109 (0%)

Query: 97 PSSSSDDESSPPSKIETPESPAVDSVPKRKTPSPVSAVTAAGKHYROVRPWN 156
P+SSSD+ ++ + + E ++ K+ S + + + + YRGRV R W

Sbjct: 10 PTSSSSDODATTSTTHLSEPAAPRNNTKRRDSSAASSSSM+QHPPYVRQVRMRSW 69

Query: 157 GPKAAABIRDPAKNGARVWLTGTPTEADAALYDRAAPRMRGSALLNPP 205
GK++ +BIR P K R+WLGT P T A+ AA + +GS A+LNPP

Sbjct: 70 GRKWSBIRQPRK-K-TRIMLGTPVTDMAARAHDAVAAALTIKGSSAVLNPP 117

>G12 (Amino Acid Sequence) (gf=1)
Length = 196

Score = 80.1 bits (196), Expect = 8e-17
Identities = 43/92 (46%), Positives = 55/92 (59%), Gaps = 6/92 (6%)

Query: 114 IETPESPAVDSVPKRKTPSPVSAVTAAGKHYROVRPWNKPAAEIRDPAKNGARV 173
+ET A V S P V+A T K Y+G+R W GK+ AEIR+P K +R+
MSTETAVVTPSPVTPAVT---+VAATRTRKDPKYGIRKKGKVAETRPRKR-SRI 54

Query: 174 WLGTPETAADAALYDRAAPRMRGSALLNPP 205
WLG++ T E AA AND A P +RG A LNPP

Sbjct: 55 WLGSYSTPEAAARAYDATTAVYLRGSPARLNPP 86

>G1141 (Amino Acid Sequence) (gf=1)
Length = 330

Score = 79.7 bits (195), Expect = 1e-16
Identities = 42/63 (66%), Positives = 46/63 (72%), Gaps = 1/63 (1%)

Query: 148 YRGVQRQPRNGKFAAEIRDPAKNGARVWLTGTPTEADAALYDRAAPRMRGSALLNPP 207
+RGVQR W GK+ AEIR+P K ARWLGPH TAE-AAVY AA ++ G A LN P

Sbjct: 78 FRGVQRQKWWKAETRPEKKAEEASSTMSSTSS 84

Query: 208 YNS 210
Sbjct: 137 VGS 139

>G2138 (Amino Acid Sequence) (gf=1)
Length = 161

Score = 79.3 bits (194), Expect = 1e-16
Identities = 56/141 (38%), Positives = 68/141 (47%), Gaps = 22/141 (15%)

Query: 96 EPSSSSDDEDRSS-----+PSVKLIEPEPAVDSVPKRKTPSPVSAVT 141
E + SSSDD + I+ +S +D + + P T

Sbjct: 13 EATDSSSDDEDTBERGASOTRERGKRLVKEIVIDPSADKLVCKTRPKIR+PAEFLKT 72

Query: 142 AAKGKHYROVRPWNKPAAEIRDPAKNGA-----+RWLGTPETAADAALYDRAAPM 195
A K YRGVQRQPRNGKFAAEIRDPAKNGA-----+RWLGT P TAE+ALAYD A+ ++

Sbjct: 73 AKTEKRYQRVQRQPRKWAIR--CGRAGACRDRDLWLGTNTAEALAYDANSIKL 130

Query: 196 RGSALLNPPAVLNSSGPPV 216
G A NF L + E V

Sbjct: 131 IGPAPTFGLPAENQEDTV 151

>G38 (Amino Acid Sequence) (gf=1)
Length = 335

Score = 79.3 bits (194), Expect = 1e-16
Identities = 45/91 (49%), Positives = 55/91 (59%), Gaps = 9/91 (9%)

Query: 123 VDSVPVKRKTPSPVSAVTAAGKHYROVRPWN 174
V+V K K + KGVK+ + + VEEVSTKGRKTPAKESKCKCMGKGPENSRCSFRGVQKNGKVAETRPENE-GSRLLW 104

Sbjct: 46 VEEVSTKGRKTPAKESKCKCMGKGPENSRCSFRGVQKNGKVAETRPENE-GSRLLW 104

Query: 175 LGTPETADAALYDRAAPRMRGSALLNPP 205
LGTP TA+AA AYD AA M G A LNPP

Sbjct: 105 LGTPTA+AA AYD AA M G A LNPP

>G975 (Amino Acid Sequence) (gf=1)
Length = 199

Score = 79.0 bits (193), Expect = 2e-16
Identities = 45/89 (51%), Positives = 54/89 (60%), Gaps = 2/89 (2%)

Query: 146 KHYREVRQPRNGKFAAEIRDPAKNGARVWLTGTPTEADAALYDRAAPRMRGSALLNPP 205
K +RGVQR W GK+ AEIR+P K KKFPRQVRQHNGWSVREIHPPLK-RNWLGTPETAEARAVLMSGRANKTNP 63

Query: 206 L-RVNSGDPDPYRISKRSKSS 233
L N+GE + SS SS+ +
Sbjct: 64 LNNNTNTGETSCKTDISASSTMSSTSS 92

>G1800 (Amino Acid Sequence) (gf=1)
Length = 277

Score = 79.2 bits (191), Expect = 3e-16
Identities = 37/58 (63%), Positives = 45/58 (76%), Gaps = 1/58 (1%)

Query: 148 YRGVQRQPRNGKFAAEIRDPAKNGARVWLTGTPTEADAALYDRAAPRMRGSALLNPP 205
YRGVQR W GK+ AEIR+P K ARWLGPH TAE-AAVY AA ++ G A LN P

Sbjct: 28 YRGVQRQPRNGKFAAEIRDPAKNGARVWLTGTPTEADAALYDRAAPRMRGSALLNPP 84

>G442 (Amino Acid Sequence) (gf=1)
Length = 244

Score = 78.3 bits (186), Expect = 1e-15
Identities = 42/92 (45%), Positives = 53/92 (56%), Gaps = 7/92 (7%)

Query: 148 YRGVQRQPRNGKFAAEIRDPAKNGARVWLTGTPTEADAALYDRAAPRMRGSALLNPP 200
+RGVQR W GK+ AEIR+P + R+WLGT P TA+ALAYDAA M G A

Sbjct: 70 FRGVQRQPRNGKFAAEIRDPAKNGARVWLTGTPTEADAALYDRAAPRMRGSALLNPP 200

Query: 201 LNPLPLRNNSGBPDPYRISKRSKSS 232
LNPP + G + S + N+ G

Sbjct: 130 RLNPPEDIGGGRKIDDEAESCGYNTKAG 161

>G1754 (Amino Acid Sequence) (gf=1)
Length = 341

Score = 75.9 bits (185), Expect = 2e-15
Identities = 49/136 (38%), Positives = 62/126 (48%), Gaps = 9/126 (7%)

Query: 127 PVKKEKTPSPVSAVTAAGK-----+HYRGVQRQPRNGKFAAEIRDPAKNGARVWLTGTF 178
P K P + R+WLGT P + RGK+ AEIR+P GAK+WLGT P

Sbjct: 43 PRSIRKPPKGSKRKGCKGKGPENGICDYRGVQRQPRNGKVAETRPENE-DGARLWLGT P 101

http://waldanc.mendeley.com/ugj-bin/nph-blst.ncbi
673 (Length: 268)

Query: 179 ETADALAYDRAAFMRGSRALLNPLRVNSCEPDVYRKSKRSSPSSSENENGAFKRR 238
Sbjct: 102 SSTEALALATEAKAYQGSARANLPEITNRSSSTAATVSGVTAFSDESEVCARED 161
Sbjct: 239 TVAAGG 244
Sbjct: 162 TMASSG 167

>G1090 (Amino Acid Sequence) (gf=1)
Length = 184

Score = 75.9 bits (185), Expect = 2e-15
Identities = 36/63 (57%), Positives = 46/63 (72%), Gaps = 1/63 (1%)

Query: 148 YGYVQRQPGKPAABIRDPAKNGKARVWLGTPETADAALAYDRAAFMRGSRALLNPLR 207
Sbjct: 20 YRG+R+ WGR+ +EIN+P K R+WLGT+*TAE AA AYD AA +RG LNP
Sbjct: 20 YRG+RREKPKGKWWSEIREPGK-K-TRIVGTSYETAAVAAVDAALHLRGCTNLNPPL 78

Query: 208 VNS 210
Sbjct: 79 VDS 81

>G1007 (Amino Acid Sequence) (gf=1)
Length = 225

Score = 75.9 bits (185), Expect = 2e-15
Identities = 43/83 (51%), Positives = 53/83 (63%), Gaps = 2/83 (2%)

Query: 123 VDSVYVKBEKTSVPSAATVAAKGHYGRVORPGKPAAEIRDPAKNGKARVWLGTPETAE 182
Sbjct: 2 VDS E +S T KG YRG R WKG+ +EIR+P K +R+WLGT PTE
Sbjct: 2 VDSHGSPTBECSSRCKRKATKRGV-YRGARMRISKGKWWSEIREPRK-SRMLGTPETAE 59

Query: 183 DAALAYDRAAFMRGSRALLNPP 205
Sbjct: 60 AA A-D AA +GS A+INPP 82

>G2299 (Amino Acid Sequence) (gf=1)
Length = 236

Score = 75.5 bits (184), Expect = 2e-15
Identities = 41/79 (51%), Positives = 54/79 (67%), Gaps = 4/79 (5%)

Query: 145 GH- YRGVQRQPGKPAABIRDPAKNGKARVWLGTPETADAALAYDRAAFMRGSRALL 202
Sbjct: 46 GH- YRGVQRQPGKPAABIRDPAKNGKARVWLGTPETADAALAYDRAAFMRGSRALL 202
Sbjct: 46 GH- YRGVQRQPGKPAABIRDPAKNGKARVWLGTPETADAALAYDRAAFMRGSRALL 202

Query: 203 NPLRVNSCEPDVYRKSKRSSPSSSENENGAFKRR 221
Sbjct: 105 NPPELADS-FPRVVLSPR 122

>G116 (Amino Acid Sequence) (gf=1)
Length = 218

Score = 75.5 bits (184), Expect = 2e-15
Identities = 48/116 (41%), Positives = 71/116 (60%), Gaps = 21/116 (18%)

Query: 129 KKTKTSVPSAATVAAKGKHH - YRGVQRQPGKPAABIRDPAKNGKARVWLGTPETADAAL 186
Sbjct: 20 EEEKKPKVQDPS- - - GKH YRGVQRQPGKPAABIRDPAKNGKARVWLGTPETADAAL 186
Sbjct: 20 EEEKKPKVQDPS- - - GKH YRGVQRQPGKPAABIRDPAKNGKARVWLGTPETADAAL 186
Sbjct: 20 EEEKKPKVQDPS- - - GKH YRGVQRQPGKPAABIRDPAKNGKARVWLGTPETADAAL 186

<http://mendelbio.com/cgi-bin/nph-blast.ncbi>

Identities = 42/85 (49%), Positives = 52/85 (60%), Gaps = 2/85 (2%)

Query: 146 KHYGVQRQPMGKPAABIRDPAKNGARVWLGTPETADAALAYDRAAFRMRGSRALNPP 205
Sbjct: 5 K+KPGVQRQPMGKPAABIRDPAKNGARVWLGTPETADAALAYDRAAFRMRGSRALNPP 63

Query: 206 LRVNSCEPPVYRKSRSFSSNE 230

Sbjct: 64 V-IKNSNSLIEINSLRSPLSLE 87

>G1386 (Amino Acid Sequence) (gf=1)
Length = 194

Score = 73.9 bits (180), Expect = 6e-15

Identities = 37/77 (48%), Positives = 50/77 (64%), Gaps = 1/77 (1%)

Query: 129 KKBKTTSVPAAVTAAGKSHPMKPGKFAABIRDPAKNGARVWLGTPETADAALAYDRAAFRMRGSRALNPP 188
Sbjct: 26 KKKRAKDDDDDEKVSKHPPMFKPGKFAABIRDPAKNGARVWLGTPETADAALAYDRAAFRMRGSRALNPP 84

Query: 189 DRAAFRMRGSRALNPP 205

Sbjct: 85 DVAALAIKGSAAHLNPP 101

>G1379 (Amino Acid Sequence) (gf=1)
Length = 184

Score = 73.2 bits (178), Expect = 1e-14

Identities = 35/70 (50%), Positives = 47/70 (67%), Gaps = 1/70 (1%)

Query: 136 VSAANTAAKSHYKHYGTVQRQPMGKPAABIRDPAKNGARVWLGTPETADAALAYDRAAFRMRGSRALNPP 195
Sbjct: 9 VAVPTEKTRDPEYKGTRMKWKGKWAIREPNEK-SRLWLGSTPSTPEAAARAYTAVFYL 67

>G441 (Amino Acid Sequence) (gf=1)
Length = 244

Score = 73.2 bits (178), Expect = 1e-14

Identities = 34/58 (58%), Positives = 44/58 (75%), Gaps = 1/58 (1%)

Query: 148 YGVVRQPMGKPAABIRDPAKNGARVWLGTPETADAALAYDRAAFRMRGSRALNPP 205
Sbjct: 43 YRGVEMRTTWKVNVEIREPRKK-SRLWLGSTPSTPEAAARAYTAVFYL 99

>G39 (Amino Acid Sequence) (gf=1)
Length = 187

Score = 73.2 bits (178), Expect = 1e-14

Identities = 38/84 (45%), Positives = 54/84 (64%), Gaps = 5/84 (5%)

Query: 126 VPVKKEKTPVSAVTA--KGYHYGTVQRQPMGKPAABIRDPAKNGARVWLGTPETADAALAYDRAAFRMRGSRALNPP 205
Sbjct: 1 MPPSPPKSPPISSSLKGKHEDKPCKYRGVCRKRSWKGKWTBIRVP-KTGRRIWGSYDAP 59

>G21 (Amino Acid Sequence) (gf=1)
Length = 295

>G2583 (Amino Acid Sequence) (gf=1)
Length = 189

Score = 72.8 bits (177), Expect = 1e-14

Identities = 38/72 (52%), Positives = 45/72 (63%), Gaps = 1/72 (1%)

Query: 146 KHYGVQRQPMGKPAABIRDPAKNGARVWLGTPETADAALAYDRAAFRMRGSRALNPP 205

Sbjct: 5 K+KPGVQRQPMGKPAABIRDPAKNGARVWLGTPETADAALAYDRAAFRMRGSRALNPP 63

>G1846 (Amino Acid Sequence) (gf=1)
Length = 221

Score = 72.8 bits (177), Expect = 1e-14

Identities = 37/74 (50%), Positives = 51/74 (68%), Gaps = 2/74 (2%)

Query: 148 YGVVRQPMGKPAABIRDPAKNGARVWLGTPETADAALAYDRAAFRMRGSRALNPP 207

Sbjct: 19 YGVVRQPMGKPAABIRDPAKNGARVWLGTPETADAALAYDRAAFRMRGSRALNPP-E 76

>G1755 (Amino Acid Sequence) (gf=1)
Length = 174

Score = 72.4 bits (176), Expect = 2e-14

Identities = 44/103 (42%), Positives = 60/103 (57%), Gaps = 14/103 (13%)

Query: 208 VNSGEPDPYRISK 221

Sbjct: 77 LSKLIPRPLSPLSPR 90

>G1277 (Amino Acid Sequence) (gf=1)
Length = 153

Score = 72.0 bits (175), Expect = 2e-14

Identities = 34/67 (50%), Positives = 46/67 (67%), Gaps = 1/67 (1%)

Query: 139 AVTAARKHRYGTVQRQPMGKPAABIRDPAKNGARVWLGTPETADAALAYDRAAFRMRGS 198

Sbjct: 12 AVTMKREREPDKTRWKWVABIREPNEK-SRLWLGSTPSTPEAAARAYTAVFYL 70

>G20 (Amino Acid Sequence) (gf=1)
Length = 295

<http://haldane.mendelbio.com/cgi-bin/nph-blast.ncbi>

G28 (Length: 268)

<http://haldane.mendelbio.com/cgi-bin/nph-blast.ncbi>

G28 (Length: 268)

Query: 157 GKEPAERIDPAKNGARVILSTPEATAEDALAYDAAFRMGRSALLNPFRLVNS 210
 G + +EIR P + R+WLG+ TAB AA AYD A +G A LNP P + S
 Sbjct: 59 GSNVSETRAPNQK-TRIMLGSYTAALAARAYDVALCLKGPKANLNFTSSS 111

>G869 (Amino Acid Sequence) (gf=1)
 Length = 324

Score = 67.8 bits (164), Expect = 4e-13
 Identities = 41/83 (49%), Positives = 53/83 (63%), Gaps = 5/83 (6%)
 Query: 108 SPPSVK1-ETPESPAVDTSPVKKETKPSAATTAAGKRYVRQRPNGKPAEIRDP 166
 Sbjct: 75 NPPSMBEVSOPSESSQDST-TKTDGKIAASASPAPRKKEPV-GVTRQRKGKWAFAIRDP 131
 Query: 167 AKNGARYVWLGTPFETAEDALAYD 189
 Sbjct: 132 IKK-TRWLGTPTDLEAAKAYD 153

>G40 (Amino Acid Sequence) (gf=1)
 Length = 213

Score = 67.4 bits (163), Expect = 6e-13
 Identities = 34/57 (59%), Positives = 42/57 (73%), Gaps = 1/57 (1%)
 Query: 148 YRGVRQRPGKPAEIRDPAKNGARVWLGTPTEDALAYDAAFRMGRSALLNP 204
 Sbjct: 48 YRGVRQRSGKWSVSEREPNNK-TRIMLGTPTAEMARAHVANIALRGRSACLN 103

>G41 (Amino Acid Sequence) (gf=1)
 Length = 207

Score = 66.6 bits (161), Expect = 1e-12
 Identities = 34/57 (59%), Positives = 41/57 (71%), Gaps = 1/57 (1%)
 Query: 148 YRGVRQRPGKPAEIRDPAKNGARVWLGTPTEDALAYDAAFRMGRSALLNP 204
 Sbjct: 42 YRGVRQRSGKWSVSEREPNNK-TRIMLGTPTAEMARAHVANIALRGRSACLN 97

>G2067 (Amino Acid Sequence) (gf=1)
 Length = 244

Score = 66.2 bits (160), Expect = 1e-12
 Identities = 37/90 (41%), Positives = 48/90 (53%), Gaps = 1/90 (1%)
 Query: 116 TPEPAVDTSPVKKETKPSAATTAAGKRYVRQRPNGKPAEIRDPANGARVWL 175
 Sbjct: 11 TISSSLRSHSSSSSSSTS+K K Y+GVR R WG + EIR P + R+WL 69
 Query: 176 GTFFETAEDALAYDAAFRMGRSALLNP 205
 Sbjct: 70 GSYSTAEEAARAYDVALCLKGPKANLNFP 99

Database: pfGene
 Posted date: Aug 27, 2002 10:23 AM
 Number of letters in database: 551,722
 Number of sequences in database: 1566

Lambda K H 0.313 0.129 0.373